The vesicular glutamate transporter (VGLUT): heterologous expression, proteoliposome, computational and mass spectral studies by Chao, Chih-Kai
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2008 
The vesicular glutamate transporter (VGLUT): heterologous 
expression, proteoliposome, computational and mass spectral 
studies 
Chih-Kai Chao 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Chao, Chih-Kai, "The vesicular glutamate transporter (VGLUT): heterologous expression, proteoliposome, 
computational and mass spectral studies" (2008). Graduate Student Theses, Dissertations, & 
Professional Papers. 1107. 
https://scholarworks.umt.edu/etd/1107 
This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
THE VESICULAR GLUTAMATE TRANSPORTER (VGLUT): 
HETEROLOGOUS EXPRESSION, PROTEOLIPOSOME, 
COMPUTATIONAL AND MASS SPECTRAL STUDIES 
By 
Chih-Kai Chao 
Master of Science in Pharmaceutical Sciences, National Taiwan University, Taiwan, 1997 
Bachelor of Science in Pharmacy, China Medical College, Taiwan, 1991 
 
Dissertation 
presented in partial fulfillment of the requirements 
for the degree of 
 
Doctor of Philosophy 
in Pharmacology/Pharmaceutical Sciences 
 







Dr. Perry J. Brown, Associate Provost 
Graduate Education 
 
Dr. Charles M. Thompson, Chair 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Mark L. Grimes 
Department of Biological Sciences 
 
Dr. Diana I. Lurie 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Keith K. Parker 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. David J. Poulsen 



























All Rights Reserved 
 ii
Chao, Chih-Kai, Ph.D., Autumn 2008 Pharmacology/Pharmaceutical Sciences 
 
The vesicular glutamate transporter (VGLUT): heterologous expression, proteoliposome, 
computational and mass spectral studies 
 
Chairperson:  Charles M. Thompson, Ph.D. 
 
Vesicular glutamate transporters (VGLUTs) are integral membrane proteins that uptake 
glutamate into synaptic vesicles and are involved in glutamatergic neurotransmission.  
Since VGLUTs were identified and cloned, efforts have been made to characterize their 
functional roles.  However, due to experimental limitations, the structural features of 
VGLUT protein remain unclear.  In an attempt to better understand VGLUTs, 
computational and biochemical approaches were employed to characterize them.  
Plasmid DNA encoding rat VGLUT1 was constructed, amplified and expressed in Pichia 
pastoris to produce VGLUT1 protein.  Immobilized metal affinity chromatography 
(IMAC) was employed to purify the protein for structural analysis by mass spectrometry 
and to develop a functional transporting system, VGLUT1 proteoliposomes.  
Transmembrane topology and homology models of VGLUT1 were generated by web-
based and in-house programs.  The computational analysis implies that VGLUT1 protein 
appears to have 12-transmembrane domains.  Chemical and enzymatic cleavages and 
mass spectral analysis of denatured and proteoliposome-reconstituted VGLUT1 protein 
show that the experimental results are consistent with the computational models.  These 
results provide basic insight into VGLUT protein structure for neuropharmacology 
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CHAPTER 1: GENERAL BACKGROUND AND SIGNIFICANCE 
 
1.1 L-Glutamate: a Neurotransmitter in the Brain 
 
L-Glutamate (Glu) was first discovered as a taste substance in seaweed (Ikeda 
1909) and its transport mechanism in isolated brain tissue was described as early as 
almost six decades ago (Stern 1949).  It took years of effort undertakings to dispel the 
doubt regarding the transmitter role of L-glutamate as the major excitatory 
neurotransmitter in the central nervous system (Curtis 1960; Okamoto 1972; De 
Belleroche 1973; Kanner 1978; Sandoval 1978; Karppinen 1979; Cotman 1981). 
L-Glutamate is involved in learning, memory, and neural plasticity, epilepsy, 
ischemic brain damage, neural degeneration and neurotoxicity (Meldrum 2000; 
Obrenovitch 2000; Miyamoto 2003; Hynd 2004).  Synthesized in the cytoplasm, stored in 
synaptic vesicles by the uptake system of vesicular glutamate transporters (VGLUTs) and 
then released into the synaptic cleft, L-glutamate activates ionotropic glutamate receptors 
(iGluRs) for fast excitatory neurotransmission as well as metabotropic glutamate 
receptors (mGluRs) for slower modulatory affects on neurotransmission.  Its action is 
terminated by sodium-dependent glutamate transporters (excitatory amino acid 
transporters, EAATs) located on the plasma membrane of neurons and glial cells. 
EAATs are responsible for removing L-glutamate from the extracellular space.  
L-Glutamate is then taken up into glial cells and transformed to L-glutamine (Gln) which 
is then transported back into neurons where it is converted to L-glutamate and loaded into 
synaptic vesicles by the VGLUTs.  It is believed that most of the glutamate is released 
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synaptically and repackaged into synaptic vesicles through this glutamate-glutamine 
cycle (Shigeri 2004) (Figure 1.1). 
 
 
 = L-glutamate       = L-glutamine 
 
Figure 1.1 Glutamate-glutamine cycle.  L-Glu is stored in synaptic vesicles and 
released to the synaptic cleft to activate iGluRs and mGluRs for 
neurotransmission.  The action of L-Glu is terminated by EAATs.  In the 
glial cell, L-Glu is transformed to L-Gln which is then transported into the 
presynaptic neuron where L-Gln is converted to L-Glu and loaded into 




1.2 Structural Features of Vesicular Glutamate Transporters 
 
Vesicular glutamate transporters are integral membrane proteins and have been 
classified in the family of major facilitator superfamily (MFS) (Marger 1993; Pao 1998).  
Although they are distinctly expressed (Table 1.1), the three VGLUT subtypes share high 
sequence homology (74-82% identity) with one another (Figure 1.2) (Reimer 2004). 
 
 
Figure 1.2 Multiple sequence alignment of human VGLUTs.  Protein sequences were 
obtained from NCBI database (http://www.ncbi.nlm.nih.gov/).  The 
sequence alignment was generated by MultAlin (Corpet 1988).  Conserved 
sequence blocks are shown as white letters in black background.  
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Table 1.1 Distribution of vesicular glutamate transporters 
Subtype VGLUT1 VGLUT2 VGLUT3 
Tissue distribution Brain, pineal gland 
and pancreas 
Brain, pineal gland, 
pancreas, stomach 
and intestine 
Brain and liver 
Distribution 
































Adapted from Hisano (2003). 
 
According to the transporter classification schemes (Marger 1993), the VGLUTs 
most likely have a similar transport mechanism to glycerol-3-phosphate (G3P) transporter 
(GlpT), which is classified as an organic phosphate/inorganic phosphate (Pi) antiporter.  
Huang and colleagues (2003) proposed an alternating-access mechanism which employs 
conformational changes (outward- and inward-facing conformations, Co and Ci) similar 
to a "rocker-switch".  This putative mechanism results in a transport scheme as depicted 






Figure 1.3 Putative reaction cycle of substrate translocation of GlpT.  Adapted from 
Huang (2003).  The substrates (Pi and G3P) and the key substrate binding 
sites (R45 and R269) are labeled.  Co: outward-facing conformation; 
Ci: inward-facing conformation. 
 
VGLUT is believed to exchange one proton for one glutamate molecule during the 
transport process (Reimer 2001).  Recently, Jung and colleagues (2006) reported 
experimental evidence of the membrane topology of VGLUT2 exogenously expressed in 
COS7 cells.  The plasma membrane was permeabilized with detergents (digitonin and 
Triton X-100, respectively) and probed with antibodies specific to the N-terminus (Anti-
N), C-terminus (Anti-C) and the first putative loop (Anti-L).  It was suggested that both 
the amino and carboxyl terminals are exposed on the cytoplasmic surface (Figure 1.4), 






Figure 1.4 Proposed 12-transmembrane VGLUT model with amino and carboxyl 
terminals exposed on the cytoplasmic surface. The protein segments probed 
by antibodies (Anti-N, anti-C and Anti-L) are indicated by arrows. Adapted 
from Jung (2006). 
 
Recently, mutational analyses of the structure-function relationship of VGLUT2, 
reconstituted in proteoliposomes show that R88, H128, R184, E191 and R322 are critical 
residues for L-glutamate transport activity but not as important for inorganic phosphate 
(Pi) transport (Figure 1.5).  Site mutation studies suggest that VGLUT2 has two 
independent transport machineries: a ∆ψ-dependent L-glutamate uptake and a sodium-
dependent Pi uptake (Juge 2006).  However, docking studies of a VGLUT1 homology 
model (using GlpT as the template) indicate two different possible binding residues (H120 






Figure 1.5 Proposed substrate binding region of VGLUT2. The critical binding 
residues are indicated by arrows.  Left: side view; right: top view.  
Adapted from Juge (2006). 
 
Vardy and colleagues (2004) hypothesized that all members of the MFS share a 
similar structure and their models are in good agreement with the experimental data.  
Despite the low sequence identity, X-ray crystal structures of lactose permease 
transporter (LacY) (Abramson 2003) and glycerol-3-phosphate transporter (Huang 2003), 
these two MFS membrane proteins show high structural homology with 12-
transmembrane domains.  To date, X-ray structures of three MFS proteins (LacY, GlpT 
and EmrD) have been determined.  They are possible templates for the homology 
(comparative) modeling of VGLUTs. 
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1.3 Functional Properties of Vesicular Glutamate Transporters 
 
A unique synaptosomal fraction of rat cerebral cortical slices was found to 
selectively transport glutamate into vesicles after the equilibrium sedimentation in 
sucrose density gradients (Wofsey 1971).  The transporter proteins responsible for the 
glutamate uptake were not identified until the 1990s. 
To date, three subtypes of vesicular glutamate transporter (VGLUTs 1, 2 and 3) 
have been identified (Ni 1994, 1996; Aihara 2000; Hayashi 2001; Fremeau 2002; 
Takamori 2002).  VGLUT1 and 2 were previously described as brain-specific or 
differentiation-associated sodium-dependent inorganic phosphate transporters (BNPI or 
DNPI) respectively, but later characterized as highly specific glutamate transporters with 
a Km approximately 1–2 mM that is 1000-fold lower than that of the EAATs (Km 4–40 
µM).  VGLUT activity depends on the driving force of the vesicular proton 
electrochemical gradient (∆pH and ∆ψ), generated by the vesicular proton ATPase (Naito 
1985; Tabb 1992; Moriyama 1995) (Figure 1.6).  It has been shown that the amount of 
VGLUT expression influences the presynaptic release of L-glutamate (Daniels 2004; 
Wojcik 2004).  Antidepressant drug and electroconvulsive shock treatment have been 
shown to increase expression of VGLUT (Tordera 2005), however, the pathological role 






Figure 1.6 A representative model for the vesicular accumulation of glutamate.  The 
uptake of L-glutamate into the synaptic vesicle depends on the 
electrochemical gradient (∆pH and ∆ψ) generated by the vesicular H
+
- 
ATPase with chloride ion (Cl
-
) as the modulator. 
 
VGLUT also has a biphasic dependence on chloride ion (Cl-), such that low 
concentrations activate uptake while high concentrations are inhibitory (Figure 1.6).  
Chloride is thought to be either a counter ion of proton influx or an allosteric effector of 
the VGLUTs (Wolosker 1996).  Vesicle-associated G protein (Gαo2) has been shown to act 
on a putative regulatory chloride binding domain and shift the VGLUT maximum activity to 
a lower chloride concentration.  It is thought that Gαo2 acts in a manner to prevent 
overexcitability by keeping VGLUT in a less efficient state (Winter 2005). 
 
 
1.4 Mass spectrometry of proteins 
 
Mass spectrometry-based strategies for protein structural analyses have become 
powerful tools for protein identification and characterization (Ball et al. 1998; Yates 2004; 
Wysocki et al. 2005).  Basically, a mass spectrometer consists of the three units: (1) ion 
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source, (2) the mass analyzer and (3) the ion detection system.  Theoretically, biological 
molecules (e.g. proteins and peptides) need to be converted into ions by an ionization 
method such as electrospray ionization (ESI) or matrix assisted laser 
desorption/ionization (MALDI).  Then, based on their mass-to-charge (m/z) ratios and 
dynamic movement in the electrical or magnetic field, the ions are separated in the mass 
analyzer such as quadropoles or a time-of-flight (TOF) analyzer, and strike the ion 
detection system to produce events of signals which are then amplified by an electron 
multiplier for recording.  Small molecules, peptides and even some whole proteins can be 
analyzed and characterized by mass spectrometry for proteomic studies (Liebler 2002). 
A general proteomic experiment includes five stages: (1) purification of proteins, 
(2) cleavage of proteins, (3) separation of peptides, (4) mass spectrometric analysis, and 
(5) data processing.  Proteins isolated from tissues or an in vitro overexpressed system 
are purified by centrifugal fractionation, affinity chromatography or gel electrophoresis.  
Then, the proteins are degraded chemically (e.g., cyanogens bromide) or enzymatically 
(e.g., trypsin) to generate peptides that can be further separated by high-performance 
liquid chromatography (HPLC) and eluted into an electrospray ion source.  After 
ionization, charged peptides enter a mass spectrometer and the mass spectra of the 
peptides or peptide fragments are acquired (MS or MS/MS spectra).  The data are 
processed by a protein/peptide identification algorithm for protein identification or 





1.5 Research Goal 
 
The pharmacology of VGLUTs and their role in neurological diseases is poorly 
understood.  To better understand VGLUTs, structural details are an important step.  "If 
you want to understand function, study structure" (Crick 1988).  The orientation of 
VGLUT protein in synaptic vesicles, its transmembrane domains, substrate binding sites, 
and mechanism of action is still unclear.  The goal is to further advance the current 
understanding of VGLUT structure by an integrative battery of computational and 
biochemical approaches (Figure 1.7).  Studies are initiated with protein expression and 
purification as well as building transmembrane and homology models as the hypothesis.  
Purified VGLUT protein is reconstituted into proteoliposomes to test the function of 
glutamate uptake, and to determine the sequence information by proteolysis and mass 
spectrometry.  The homology and transmembrane models are refined and modified by 
mass spectral analysis. 
 
 




The specific aims are: 
(1) to show that we can exogenously express rat VGLUT1 protein in Pichia 
pastoris, purify the protein using immobilized metal ion affinity 
chromatography (IMAC), and reconstitute the purified VGLUT1 protein in 
proteoliposomes, 
(2) to perform sequence alignments and phylogenetic analysis of VGLUTs to 
generate two-dimensional transmembrane and homology models of VGLUT1, 
(3) to determine key sequences in the VGLUT1 protein structure with and 
without reconstitution into proteoliposomes by mass spectrometry that reveals 
structural clues, and 
(4) to refine and advance the model postulated in (2) with mass spectrometry and 
computational experiments. 
 
The experimental results would provide fundamental structural features of 
VGLUT protein and offer the basic pharmacophore information for drug design for the 
treatment of glutamate-related neural diseases. 
In this dissertation, results of VGLUT1 heterologous expression, isolation, 
purification, computational modeling, reconstitution into proteoliposomes, functional and 








Crude synaptic vesicle preparations can be prepared from adult rat forebrain 
(Huttner 1983; Coughenour 2004).  Due to experimental limits, however, analysis of the 
vesicle preparation does not differentiate between the various VGLUT isoforms, and it is 
difficult to resolve the individual kinetics of uptake of each isoform.  VGLUT protein has 
been functionally expressed in PC12 and COS7 cells (Bellocchio 2000; Hayashi 2001).  
One of the major drawbacks of using these cells is the insufficient protein yield for 
structural analysis.  Anderson (2004) used High Five insect cells to produce a high 
amount of recombinant VGLUT1 protein, but the protein expressed in the insect cells did 
not show glutamate uptake activity.  This functional failure could be possibly explained 
by a lack of post-translational modifications. 
Escherichia coli has been used to express recombinant proteins for decades.  The 
major disadvantage of its application is deficiency of membrane-bound organelles for 
post-translational modifications, which are suspected to be critical for the function of 
VGLUT protein (Anderson 2004).  Pichia pastoris is able to generate post-translational 
modifications similar to human protein modifications, and this species of yeast has been 
used to successfully express ample quantity of recombinant membrane proteins (Weiss 
1998; Feng 2002). 
VGLUT1 is an integral membrane protein immobilized in the environment of 
lipid bilayer, hardly dissolving in aqueous solution.  To isolate a membrane protein, the 
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first challenge is to separate it from membrane or subcellular organelles such as 
endoplasmic reticulum, Golgi and vacuoles.  Although the extraction process causes loss 
of membrane protein, cosolvents (e.g. glycerol) and surfactants (e.g. SDS, Triton X-100 
and DDM) have been used to successfully isolate membrane proteins.  The purity of an 
isolated membrane protein can be achieved by chromatographic methoding include size-
exclusion, ion-exchange, reverse-phase, hydrophobic interaction and affinity 
chromatography (Scopes 1994). 
Immobilized metal ion affinity chromatography (IMAC) has been developed to 
purify recombinant proteins containing an affinity tag (Porath 1975).  The affinity 
interaction (Figure 2.1) occurs between the electron donor (basic) groups of specific 
amino acid residues (e.g. hexahistidine tag) and coordination sites of transition metal ions 
(e.g. Co2+, Ni2+ and Zn2+) immobilized in a matrix (iminodiacetic acid, IDA).  Affinity-
tagged protein is purified by binding to the immobilized metal ions, washing off non-
specific binding proteins and elution with an imidazole gradient (competitive ligands to 
the transition metal ions). 
Recombinant c-myc/hexahistidine-tagged VGLUT1 was heterologously expressed 
in Pichia pastoris strain X-33.  The myc and hexahistidine epitopes in the recombinant 
VGLUT1 protein serve as tags for identification and purification.  Purification of 
recombinant c-myc/His6-tagged rVGLUT1 protein was performed by IMAC.  The 
experimental parameters were optimized to obtain an ample source of VGLUT1 protein 





Figure 2.1 The theoretical interaction between nickel-chelating iminodiacetate (IDA) 
resin and histidyl residues.  The hexahistidine epitopes in the recombinant 
VGLUT1 protein serve as tags for protein purification by immobilized metal 
ion affinity chromatography (IMAC). 
 
To identify rVGLUT1 protein isolated and purified from the transformed Pichia 
pastoris, Western blot (immunodetection) and MALDI-TOF mass spectrometry were 
employed to characterize the purified protein.  For MS analysis, the protein was cleaved 





2.2 Materials and Methods 
 
2.2.1 Materials 
Chemicals were obtained from Sigma (St. Louis, MO) unless otherwise stated.  
The rat brain cDNA library was obtained from Clontech (Mountain View, CA).  Yeast 
shuttle vector pGAPZB, Escherichia coli strain DH5R, Pichia pastoris strain X-33, and 
Zeocin® were obtained from Invitrogen (Carlsbad, CA).  Restriction enzymes and DNA 
ligase were obtained from Promega (Madison, WI).  Plasmid Maxi Kit was obtained from 
Qiagen (Valencia, CA).  Zeocin® were obtained from Invitrogen (Carlsbad, CA).  
Zymolase 100T was obtained from Seikagaku America (Rockville, MD).  cØmplete Mini 
EDTA-free protease inhibitor mixture was obtained from Roche Molecular Biochemicals 
(Indianapolis, IN).  Laemmli sample buffer, 10% precast polyacrylamide gel, Coomassie 
Blue reagent and PVDF membrane were obtained from Bio-Rad (Hercules, CA).  
Polyclonal anti-VGLUT1 (N-terminal) antibody was obtained from Alpha Diagnostic 
(San Antonio, TX).  Horseradish peroxidase-conjugated anti-IgG antibody was obtained 
from Cell Signaling (Beverly, MA).  HiTrap Chelating HP Columns and enhanced 
chemiluminescence reagents (ECL Plus®) were obtained from Amersham (Piscataway, 
NJ).  Sequencing-grade modified trypsin was obtained from Promega (Madison, WI).  
Formic acid (98%) was obtained from EM Scientific (Carson City, NV).  The solvents, 
acetonitrile and isopropanol, were both 99% and used without further purification.  




2.2.2 Cloning and plasmid DNA construction 
Pichia pastoris shuttle vector pGAPZB was employed to construct the plasmid 
DNA encoding rat VGLUT1.  Rat VGLUT1 cDNA (Genbank accession number 
U07609) was first amplified from a rat brain cDNA library by polymerase chain reaction 
(PCR) with specific primers, sense 5'-GAA TAA ACG ATG GAG TTC CGG CAG 
GAG GAG TTT-3' and antisense 5'-GCG GCC GCG TAG TCC CGG ACA GGG GGT 
G-3' in a 50 µL reaction containing 0.2 µM primers, 200 µM dNTPs, 2.5 mM MgCl2, 1 
ng of rat brain quick-clone cDNA as template, and 2.5 U Pfu Ultra DNA polymerase.  
The VGLUT1 DNA was then incorporated into the pGAPZB plasmid vector in frame 
with the C-terminal c-myc epitope and hexahistidine (His6) tag using the 5'-EcoR I and 3'-
Not I restriction recognition sites.  The DNA sequence was confirmed by plasmid DNA 
sequencing after PCR and verified by nucleotide BLAST (basic local alignment search 
tool, http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.2.3 Yeast transformation 
Plasmid DNA encoding VGLUT1 was amplified within Escherichia coli and 
purified by Plasmid Maxi Kit.  After linearization with restriction enzyme AvrII, the 
linear DNA was used to transform wild type Pichia pastoris strain X-33 with 
electroporation.  The transformation was confirmed by PCR of the genomic DNA using 




2.2.4 Crude yeast membrane preparation 
Soft-lysis method.  The transformed Pichia pastoris was grown in sterile media 
containing yeast extract, peptone, and dextrose (YEPD) at 30°C with shaking at 300 rpm 
for 48 to 60 h until the OD600 of the culture was higher than 20.  Yeast cells were 
harvested by centrifuge at 500 g for 10 min at 4°C, washed with ice-cold phosphate-
buffered saline, resuspended in the 50 mM HEPES buffer (pH 7.5, containing 1.2 M 
sorbitol, 10 mM MgCl2, 2 mM dithiothreitol and 100 mg/ml PMSF), and treated with 
Zymolase 100T at 30°C for one hour.  Spheroplasts were homogenized in the buffer (0.2 
M sorbitol, 1 mM EDTA, 100 mg/ml PMSF, 50 mM HEPES, pH 7.5).  Crude membrane 
pellets (P13) were collected by centrifuge at 13,000 g for 10 min at 4°C.  The supernatant 
was further centrifuged at 100,000 g for 10 min at 4°C to obtain the P100 pellets. 
Glass-bead method.  Yeast cells were grown and harvested by the procedures 
described previously.  The pellet was suspended in 4 volumes of 50 mM sodium 
phosphate buffer (pH 7.4) containing 10% glycerol, 1 mM PMSF, 1 mM EDTA and 
cØmplete Mini EDTA-free protease inhibitor mixture.  A half volume of acid-washed 
chilled glass beads (Sigma, St. Louis, MO) was added to the suspension, and the cells 
were disrupted by vigorous vortexing 20 times for 30 s, with intervening 30 s incubations 
on ice.  Unbroken cells were removed by centrifugation at 2,000 g for 5 min at 4 °C.  The 
crude membranes were obtained by centrifugation at 36,668 g at 4 °C for 120 min. 
 
2.2.5 IMAC purification of recombinant rVGLUT1 protein 
SDS-solubilization method.  Crude membranes were solubilized in 50 mM 
sodium phosphate buffer (pH 7.6) containing 50 mM NaCl, 20% (vol/vol) glycerol and 
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1% (wt/vol) SDS.  The His6-tagged rVGLUT1 protein was purified by IMAC using 
HiTrap Chelating HP Columns (Amersham Biosciences, Piscataway, NJ) with gradients 
of imidazole (0 to 500 mM) in 50 mM sodium phosphate buffer (pH 7.6) containing 100 
mM NaCl, 20% (vol/vol) glycerol and 1% (wt/vol) SDS.  The general scheme of IMAC 
is shown as Figure 3.2. 
CHAPS-solubilization method. Crude membranes were solubilized in 20 mM 
sodium phosphate buffer (pH 7.6) containing 50 mM NaCl, 20% (vol/vol) glycerol, 1 
mM PMSF, 1 mM EDTA and cØmplete Mini EDTA-free protease inhibitor mixture, 
3.0% CHAPS, 5% sucrose and 2.5 mM imidazole.  The resulting membrane solution was 
shaken at RT for 1 h.  After removal of the insoluble fraction by centrifugation at 20,000g for 
10 min at 20°C, the clear supernatant was bound to a HiTrap Chelating HP Column at RT.  
Unbound proteins were removed by washing with 3 column volumes of the solubilization 
buffer plus 1.0% CHAPS and 2.5 mM imidazole.  His6-tagged rVGLUT1 protein was 
eluted with 2 column volumes of solubilization buffer plus 1% CHAPS supplemented 
with gradients of imidazole (5 to 500 mM).  The eluted fractions were collected in 1.5-ml 
tubes containing 1/10 volume of 1 mM EDTA. 
The protein concentration was quantified using the Lowry method (Lowry et al. 
1951).  When necessary, fractions containing VGLUT1 protein were further purified by 
trichloroacetic acid (TCA) precipitation on ice and washed with a 1:1 (vol:vol) solution 






Figure 2.2 Scheme of purification of polyhistidine-tagged protein by an IMAC column.  
A: conditioning of nickel-chelating column; B: loading of protein sample; 
C: column washing; D: elution by an imidazole gradient. 
 
2.2.6 SDS-PAGE and Western blot 
A sample was mixed with an equal volume of Laemmli sample buffer (Bio-Rad, 
Hercules, CA) containing 5% (vol/vol) β-mercaptoethanol.  The samples were incubated 
at RT for 20 min and loaded onto a 10% precast polyacrylamide gel.  Gel electrophoresis 
was performed at 100 V for 1.5 h.  Proteins on the gel were either stained with 
Coomassie Blue or electrophoretically transferred to PVDF membrane for 
immunodetection.  VGLUT1 protein on the membrane was detected by probing with 
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either a polyclonal anti-VGLUT1 or anti-myc antibody (Mountain View, CA), followed 
by probing with a horseradish peroxidase-conjugated anti-IgG antibody. Protein bands 
were visualized with an enhanced chemiluminescence reagent, ECL Plus®. 
 
2.2.7 Protein digestion 
The purified VGLUT1 protein was TCA-precipitated and dissolved by sonication 
in 50 mM ammonium bicarbonate (pH 8.0) to make the protein concentration 1 mg/ml.  
Endoproteinase Glu-C (V8), trypsin or both were added to the protein solution, followed 
by an incubation at 37ºC for 15 h.  For cyanogen bromide (CNBr) digestion, the protein 
was dissolved in 70% trifluroacetic acid (TFA) and incubated in darkness at RT for 48 h.  
Methanol was added in the digestion buffer to facilitate the enzymatic digestion (V8 and 
trypsin). 
 
2.2.8 MALDI-TOF MS analysis 
Aliquots of the digestion solution were mixed 1:1 with α-cyano-4-
hydroxycinnamic acid (CHCA), spotted on the sample plate and analyzed by the 
MALDI-TOF mass spectrometer (ABI Voyager DE STR, Applied Biosystems, Foster 
City, CA) with linear or reflectron mode.  The mass spectra were processed by Data 
Explorer (Applied Biosystems, Foster City, CA) and peptide mass values from the digests 
of VGLUT1 protein were processed by the daemon version of MASCOT (Perkins et al. 




2.3 Results and Discussion 
 
2.3.1 Initial VGLUT1 protein purification 
Pichia pastoris strain X-33 was successfully transformed to express rVGLUT1 
protein with the c-myc/hexahistidine tag (Cox 2008).  Initial purification of the recombinant 
rVGLUT1 protein failed to obtain acceptable quality of the purified protein.  Buffers for 
IMAC purification were composed of 20 mM sodium phosphate, 500 mM sodium chloride, 
1% (w/v) DDM and imidazole (5 mM for binding and 500 mM for elution).  According to 
the Coomassie Blue staining, the purity of the recombinant rVGLUT1 protein was doubtful; 
protein aggregation and degradation were suspected (Figure 2.3).  The expected rVGLUT1 
band (64 kD) is located between the protein standard markers 50 and 75 kD.  Bands of the 
elution sample (lane 4 in Figure 2.3), higher or lower than the expected size, imply protein 




Figure 2.3 Coomassie Blue staining analysis of the recombinant rVGLUT1 protein 
purified by an initial IMAC method. Lane 1: protein standards; 2, 3: column 
wash; 4, 5:elution.  Crude membranes were prepared by the soft-lysis 
method.  The expected rVGLUT1 band is indicated by a left arrow. 
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2.3.2 Protein aggregation and degradation during IMAC purification 
Multiple bands shown in the Coomassie Blue staining (Figure 2.3) implies the 
aggregation and non-specific interaction of the recombinant rVGLUT1 protein during 
purification.  The exact binding mechanism of the His6-tag to the nickel-chelating column 
remains unclear.  Hydrophobic segments of the rVGLUT1 protein possibly affected the 
interaction between histidyl residues and nickel ion immobilized on the column resin.  
Lack of IMAC-binding efficiency has been found in the aggregated rVGLUT1 protein 
which was washed out of the nickel-chelating column (Figure 2.4).  It is possible that the 
His6-tag epitopes were hindered when the protein molecules preferentially form 
aggregates through hydrophobic interaction.  Moreover, the coordination sites of nickel 
ions have been masked due to hydrophobic molecules adsorbed by the column resin. 
 
       1           2           3 
←
 
Figure 2.4 Evidence of the lack of IMAC-binding efficiency of aggregated rVGLUT1 
protein by Western blot.  Lane 1: crude membrane preparation; 2: column 
wash; 3: rVGLUT1 fraction.  The protein was purified by the soft-lysis 
method.  The expected rVGLUT1 band is indicated by a left arrow. 
 
The phenomena of aggregation and non-specific interaction were reduced by 
increasing the solubility of the recombinant rVGLUT1 protein with the addition of SDS, 
a strong anionic surfactant, to the binding and elution buffers.  SDS would affect the 
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functional analysis and mass spectral analysis.  Mild surfactants such as CHAPS, DDM 
and sodium cholate are thought not to solubilize VGLUT1 protein as well as SDS, but 
affect the protein function to a less degree than SDS.  Experimental results of the 
preliminary testing led to a choice of CHAPS for IMAC purification. 
Protein degradation has been observed during the isolation, purification and 
storage of the recombinant rVGLUT1 protein.  Freeze-thaw cycles caused an increase in 
difficulty of protein reconstitution in solution.  In addition, Patel and colleagues (2005) 
showed degradation at the C-terminus, using Western blot with anti-myc antibody 
(Mountain View, CA).  To minimize the instability, addition of protease inhibitors, metal 
ion chelators (e.g. EDTA) and cosolvents (e.g. glycerol and sucrose) has been evaluated.  
Although protein aggregation was still evident in the Coomassie Blue staining, the 
quality of the recombinant rVGLUT1 protein has been improved. 
 
2.3.3 Isolation of the recombinant rVGLUT1 protein 
The recombinant rVGLUT1 protein was expressed in the P13 and P100 fractions, 
but not significantly in the cytoplasm fraction (Patel 2005) (Figure 2.5).  Preliminary 
experiments show that the P13 fraction contained the most abundant recombinant 
rVGLUT1 protein expressed in the Pichia pastoris transformant.  For structural and 
functional analysis, subcellular separation of the yeast cells appears to be unnecessary.  
The soft-lysis method is appropriate for subcellular separation but is time-consuming; the 
glass-bead method breaks the yeast cells by mechanical force and is time-efficient.  To 
test the feasibility of the time-efficient procedure, isolation methods of the recombinant 
VGLUT1 protein were compared between the soft-lysis and glass-bead methods.  Results 
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of Coomassie Blue staining show no significant difference between these two methods of 
crude membrane preparation (Figure 2.6).  Therefore, for experimental convenience, the 
glass-bead method was chosen to isolate the recombinant rVGLUT1 protein for structural 




Figure 2.5 Western blot analyses of crude membrane fractions with anti-VGLUT1 
antibody.  Lane 1: P13 fraction; 2: P100 fraction; 3: cytoplasm.  Adapted 
from Patel (2005).  The protein was purified by the soft-lysis method.  The 
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Figure 2.6 Coomassie Blue staining of SDS-polyacrylamide gels of the recombinant 
rVGLUT1 protein.  The upper: crude membrane preparation by the soft-
lysis method; the lower: by glass-bead method.  The expected rVGLUT1 
band is indicated by a left arrow. 
Lane 1, 11, 20, 30: protein standards; 
Lane 2, 21: crude membrane preparation; 
Lane 3, 22: pre-column; 
Lane 4, 23: flow-through; 
Lane 5, 24: column wash;  
Lane 6, 25, 26: eluent at 5 mM imidazole;  
Lane 7, 8, 9, 27, 28: eluent at 10 mM imidazole;  
Lane 10, 12, 13, 29, 31: eluent at 20 mM imidazole;  
Lane 14, 15, 16, 32, 33: eluent at 50 mM imidazole;  
Lane 17, 18, 19, 34, 35: eluent at 100 mM imidazole;  
Lane 36, 37: eluent at 200 mM imidazole;  




2.3.4 Identification of the IMAC-purified rVGLUT1  
The IMAC-purified rVGLUT1 protein has been identified by Western blot 
(Figure 2.4 and 2.5) and MALDI-TOF mass spectrometry.  The former provides 
VGLUT1 immunoreactivity; the latter, protein sequence information. 
The cleavage efficiency of endoproteinase Glu-C in sodium phosphate buffer was 
increased by addition of methanol (Table 2.1). Organic solvents could aid the solubility 
of the rVGLUT1 in the buffer and allow more contact between the enzyme and substrate.  
The addition of organic solvent in the digestion buffer resulted in an increase in missed 
cleavages of the protein.  Digestion with cyanogen bromide (CNBr) reached the 
maximum cleavage efficacy at 500-fold excess (molar ratio).  Less cyanogen bromide did 
not cleave VGLUT1 efficiently, whereas more CNBr produced a complex peptide 
mixture that was difficult to interpret in mass spectra (Table 2.2). 
 
Table 2.1 Cleavage efficiency of endoproteinase Glu-C in methanol. 
Methanol % Sequence coverage %* CV %# 
0 12.0 1.0 
10 14.6 4.1 
20 28.2 23.1 
40 37.4 5.8 
60 23.9 14.1 
* Average of more than 3 experiments. 




Table 2.2 Cleavage efficiency of cyanogen bromide at different ratios. 
Molar excess (fold) Sequence coverage %* CV%# 
50x 25.3 11.9 
100x 32.8 17.4 
500x 42.0 13.9 
2000x 11.1 9.6 
* Average of more than 3 experiments. 
# The coefficient of variance of the sequence coverage. 
 
Large peptides produced by Glu-C and CNBr were detected by MALDI-TOF 
mass spectrometry.  CNBr was able to cleave the C-terminal to the methione (M) in the 
predicted transmembrane regions and produced big peptides.  With Clu-C digestion, the 
N- and C-terminus of the recombinant rVGLUT1 were identified.  The overall sequence 
coverage is excellent at 86% (Figure 2.7). 
 
 
Figure 2.7 MALDI-TOF mass spectrometric analyses of rVGLUT1-HisTag digests by 
CNBr and Glu-C.  Transmembrane segments, predicted by the naïve 
transmembrane prediction algorithm (Chapter 4), are shown as white letters 
in green background.  Peptides identified are underlined cyan for CNBr, red 




The molecular weight proved to be a predictor (p < 0.05) for the capability of 
detection by MALDI-TOF mass spectrometry (Figure 2.8), whereas the grand average 
hydropathy (GRAVY) score did not.  Although small peptides might compete for 
ionization and reduce the signal intensities of large cleaved peptides, hydrophobic 
peptides might be poorly dissolved in the solid solution of the MALDI matrix and 
resistant to be ionized. 
 
 
Figure 2.8 Predicted peptides detected by MALDI-TOF mass spectrometry.  The 
VGLUT1 protein was treated with CNBr and Glu-C.  The capability of 
detection by MALDI-TOF mass spectrometry depends on the molecular 
weights of peptides. 
 
Theoretically, the recombinant rVGLUT1 has 49 cleavage sites (13 Asp and 36 
Glu) for Glu-C digestion in sodium phosphate buffer.  The local GRAVY scores of the 
amino acid sequence regions flanking the cleavage site were calculated by their 
hydrophobicity values (Kyte 1982) with a window of 5.  For example, the GRAVY score 
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of the sequence TLELS (position 32-36) is assigned to be the local GRAVY score for the 
cleavage site at the position of Glu34.  Digested peptides with an increase in distributions 
of local GRAVY scores were observed when methanol was added into the digestion 
buffer (Figure 2.9).  The variances of GRAVY scores are 0.588, 0.940, 1.34, 1.957, and 
2.174 for the groups of 0, 10, 20, 40, and 60% methanol (V/V) respectively.  Although 
their averages are similar (P = 0.308 by ANOVA), the Levene test (Levene 1960) rejects 
the hypothesis that these variances are equal (P = 0.0021).  This finding supports the 
hypothesis that methanol exposes more possible cleavage sites within both of hydrophilic 
and hydrophobic regions to endoproteinase Glu-C. 
 
 
Figure 2.9 Distributions of local GRAVY scores of the Glu-C cleavage sites.  A higher 
GRAVY score implies a more hydrophobic cleavage site.  Addition of more 
methanol to the digestion buffer probably increases the accessibility of the 




In summary, application of glass-bead crude membrane preparation and IMAC to 
isolation and purification of the recombinant rVGLUT1 protein results in a sufficient 
protein source for structural and functional analysis.  Mass spectrometry appears to be a 








Primary sequences of protein have been used to computationally predict and 
sometimes deduce structural information.  Scientists have tried to define the principles 
that govern the folding of proteins (Anfinsen 1973; Dill 1995; Barbosa 2005) and 
develop algorithms that lead to 3D structures.  The success of computational analysis 
relies on our knowledge about protein structures and the availability of the specific 
protein databases needed to make reliable predictions. 
It is believed that the identification of known similar amino acid sequences can 
infer both the structure and function of a protein.  Sequence alignment can provide the 
preliminary information of functional and structural predictions (Watson 2005).  
Sequence homologous proteins tend to have the same function (Todd 2001).  It is 
possible that two proteins with high sequence identity between them may vary in their 
function, e.g. lysozyme and α-lactalbumin (Acharya 1991).  Sequence alignments not 
only facilitate assignment of structure-conserved regions such as transmembrane domains, 
but they are also critical in generating homology models that visualize protein structures 
in three dimensions. 
Transmembrane prediction is a classic problem in computational analysis of 
proteins.  The algorithms are based on statistics, soft computing (machine learning) or 
both, and operate in a limited database of structure-known membrane proteins (see 
Materials and Methods).  Web-based prediction programs have diverse algorithms to 
 
 33
compute the predictions of transmembrane topology.  Neural networks (Rost 1995, 1996) 
and hidden Markov models (Sonnhammer 1998; Zheng 2004) have also been applied to 
this area.  Prediction methods based on sequence alignments appear superior to those 
based on single sequences when evaluated with the database of transmembrane proteins 
with known structures (Chen 2002). 
Interestingly, transmembrane predictions using hydrophobicity plots (Kyte 1982) 
still work today.  Despite these individual prediction algorithms, consensus methods have 
taken advantage of all the prediction algorithms available by simple summation methods 
and arbitrary cut-off values (Chao 2004; Cuthbertson 2005).  These consensus methods 
lack the optimization and validation for accuracy. 
In order to computationally deduce the structure of rat VGLUT1 protein, 
sequence alignments, homology modeling, in silico docking, hydrophobicity analysis and 
transmembrane predictions (web-based and in-house programs) were performed.  An 
attempt was also made to generate better sequence alignments using amino acid 
substitution matrices other than BLOSUM62, Dayhoff and PAM250 matrices that are 




3.2 Materials and Methods 
 
3.2.1 Homology models 
Tertiary structural models of rat VGLUT1 were generated by 3D-PSSM (Kelley 
2000) and CPHmodels (Lund 2002).  The protein sequence text was submitted to the 
program servers to search for sequence matches to known three-dimensional protein 
structures.  According to the resulting sequence alignments, predicted models were 
constructed using coordinates from the template structure.  The comparisons of the 
models were carried out by the STRAP sequence alignment program (Gille 2001).  In 
silico dockings were performed using PatchDock server (Schneidman-Duhovny 2003). 
 
3.2.2 Hydrophobicity analysis 
Hydropathy scalograms with a series of sliding windows of amino acid residues 
(3-99) were produced using the hydropathy scales previously published (Kyte 1982; 
Wimley 1996) and transmembrane-propensity values developed in house (Chao 2005) 
(Table 3.1 and Appendix A).  The hydrophobic score (H) of each amino acid residue of 
rVGLUT1 was calculated and weighted by Gaussian distribution by: 
 Equation 3.1 
 
 Equation 3.2 
 
where n is the position of an amino acid residue, w is an odd number for the sliding 


























acid at position n.  The computation was performed by a program on a Perl platform 
(Appendix B). 
 
Table 3.1  Hydropathy and transmembrane propensity scales of amino acids 
Amino acid Kyte-Doolittle* Wimley-White* Transmembrane-propensity# 
A 1.8 -0.50 0.8040 
C 2.5 0.02 1.2528 
D -3.5 -3.64 -0.9410 
E -3.5 -3.63 -1.3049 
F 2.8 1.71 1.0518 
G -0.4 -1.15 0.5252 
H -3.2 -2.33 1.1896 
I 4.5 1.12 1.1506 
K -3.9 -2.80 -1.2384 
L 3.8 1.25 0.8369 
M 1.9 0.67 0.9760 
N -3.5 -0.85 -0.5108 
P -1.6 -0.14 -0.4818 
Q -3.5 -0.77 -0.5108 
R -4.5 -1.81 -1.7117 
S -0.8 -0.46 -0.2877 
T -0.7 -0.25 -0.0800 
V 4.2 0.46 0.7698 
W -0.9 2.09 0.5947 
Y -1.3 0.71 0.5773 
# The hydropathy value as an indicator of the tendency of transmembrane. 
* The transmembrane propensity scale is based on the log-transformed value 
of transmembrane frequencies estimated from the set of structure-
determined transport proteins (Appendix A). 
 
3.2.3 Web-based transmembrane predictions 
Web-based programs were employed to perform transmembrane predictions.  
They are BPROMPT (Taylor 2003), DAS (Cserzo 1997), DAS-Tmfilter (Cserzo 2004), 
HMM-TM (Bagos 2006), HMMTOP (Tusnady 2001), MEMSAT (Jones 1994), 
MINNOU (Cao 2005), OrienTM (Liakopoulos 2001), PHDhtm (Rost 1995), PRED-TMR 
(Pasquier 1999), SMART (Schultz 1998), SOUSUI (Hirokawa 1998), SPLIT (Juretic 
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2002), SVMtm (Yuan 2004), TMAP (Persson 1996), TMHMM (Krogh 2001), TMpred 
(Hofmann 1993), TopPred (Claros 1994), TSEG (Kihara 1998), waveTM (Pashou 2004), 
SVMtop (Lo 2007), and ZPRED (Granseth 2006).  All the parameters were established as 
default settings. 
 
3.2.4 Consensus method for transmembrane helix prediction (CoMTraP) 
The computational work was performed by an in-house program on Perl platform.  
Structure-known transporter proteins used for CoMTraP are EmrD (PDB code 2GFP), 
GltPh (PDB code 1XFH), LeuTAa (PDB code 2A65), NhaA (PDB code 1ZCD), LacY 
(PDB code 1PV7), and GlpT (PDB code 1PW4).  They proteins were chosen because 
they are phylogenetic relatives of VGLUT1.  Web-based transmembrane prediction 
programs, BPROMPT, DAS, DAS-TMfilter, HMM-TM, HMMTOP, MEMSAT, 
MINNOU, PHDhtm, PRED-TMR2, SMART, SOSUI, SPLIT, SVMtm, TMAP, 
TMHMM, TMpred, TopPred, TSEG, waveTM, SVMtop, and ZPRED were evaluated for 
their prediction accuracy by CT (defined in Figure 3.1).  The length of a transmembrane 
segment was set from 9 to 45 amino acid residues.  CoMTraP Perl program code is 
attached as Appendix E and the computational procedures and algorithm are shown in 




Combinations of transmembrane predictions of the selected structure-
known membrane proteins from web-base programs 
↓ 
Evaluation the accuracy of each combination 
↓ 
Selection the combination with the highest accuracy 
↓ 
Transmembrane prediction of rVGLUT1 by the selected combination 
 
Scheme 3.1 The computational procedures of CoMTraP. 
 
 
Observed      -----TTTTTTTTTTTTTTTTT-TTTTTTTTTTTTTTT-------------- 
Predicted     -----TTTTTTTTTTTTTTTTTTT--------TTTTTTTTTTTTTTTTTTT- 
True positive -----TTTTTTTTTTTTTTTTT----------TTTTTT-------------- 










PT: the number of residues correctly predicted as transmembrane (true positive) 
NT: the number of residues correctly predicted as non-transmembrane (true negative) 
UT: the number of residues incorrectly predicted as non-transmembrane (false negative) 
OT: the number of residues incorrectly predicted as transmembrane (false positive) 
Figure 3.1 Transmembrane prediction accuracy determined by segment-based measure 




3.3 Results and Discussion 
 
3.3.1 Phylogenetic analysis and homology model 
The phylogenetic analysis (Figure 3.2) of structure-known transporter proteins 
and rat VGLUTs shows that glycerol-3-phosphate transporter (GlpT) is the closest 
phylogenetic relative of rat VGLUTs.  Although the sequence identity (homology) is low, 
GlpT is still the best template choice for the homology modeling of rVGLUT1. 
Both 3D-PSSM and CPHmodels programs utilized GlpT (high sequence 
homology and low expected value) as the chosen template for the homology modeling of 
rVGLUT1 (Table 3.2) and their predictions result in 12-transmembrane segments.  When 
superimposed, these two predicted tertiary rVGLUT1 structures show no important 
differences in their transmembrane structures (RMSD = 1.04 by STRAP) (Figure 3.3).  
Because the 3D-PSSM prediction shows deletions in the protein sequence, the 






Figure 3.2 The phylogenetic analysis of structure-determined transporter proteins and 
VGLUTs.  AcrB: acriflavine resistance protein B; BtuCD: vitamin B12 
transporter; EmrE: multidrug resistance protein E; GlpT: glycerol-3-
phosphate transporter; GltP: glutamate transporter homologue (Pyrococcus 
horikoshii); LacY: lactose permease transporter; MDR1: multidrug 
resistance protein 1; MDR3: multidrug resistance protein 3; MsbA: lipid 
flippase; NhaA: Na+/H+ antiporter; OxlT: oxalate transporter; Pdr5p: 
pleiotropic drug resistance 5P; SERCA1a: calcium ATPase; YvcC: 





Table 3.2  Candidate templates for homology modeling of rat VGLUT1. 
PDB code Protein % Homology§ Length* E value# 
1PW4 Glycerol-3-phosphate 
transporter from E. coli 
18 434 4.80E-06 
1PV7 Lactose permease with Tdg 13 417 0.00474 
1AR1 Paracoccus denitrificans 
two-subunit cytochrome C 
oxidase complexed with an 
antibody Fv fragment 
13 529 0.284 
1EHK Aberrant Ba3-cytochrome C 
oxidase from Thermus 
thermophilus 
13 544 0.325 
2OCC Bovine heart cytochrome C 
oxidase at the fully oxidized 
state 
12 514 0.533 
1KPK CLC chloride channel from 
E. coli 
13 450 0.568 
1FFT Ubiquinol oxidase from E. 
coli 
13 501 1.03 
1EZV Yeast cytochrome bc1 
complex co-crystallized with 
an antibody Fv-fragment 
13 385 2.58 
1BCC Cytochrome bc1 complex 
from chicken 
13 379 3.63 
1RH5 A protein conducting 
channel 
13 410 4.16 
1EE4 Yeast karyopherin 
(importin) alpha in a 
complex with a c-Myc Nls 
peptide 
9 423 5.31 
1IAL Importin alpha, mouse 9 438 5.66 
§ Amino acid sequence identity. 
* Length of amino acid sequence. 





Figure 3.3 Homology models of rVGLUT1.  Left: 3D-PSSM prediction (R40-G512); 
middle: CPHmodels prediction (R62-Q495); right: superimposition of the 




3.3.2 Candidate targets for chemical modifications 
According to the CPHmodels prediction, spatial distances not more than 20 Å 
between the side chains of amino acid residues, cysteine (sulfhydryl group) and lysine (ε-
amino group), are good chemical cross-linking targets for structural analysis.  Selected 
amino acid pairs (distance in Å) are C74-C81 (12.2), C74-C138 (17.5), C74-C190 (8.7), C74-
K196 (19.4), C74-C212 (7.5), C81-C190 (17.5), C81-C212 (16.2), C81-C452 (16.5), K106-K401 
(19.2), K106-C452 (18.2), K106-K461 (7.4), K106-K463 (14.2), C138-K140 (11.1), C138-C190 
(10.3), C138-K196 (9.5), C138-K283 (14.9), K140-C190 (19.9), K140-K196 (13.0), K140-K283 
(13.0), C190-K196 (11.2), C190-C212 (12.5), C190-K283 (20.0), K196-K272 (15.2), K196-K283 
(19.4), C313-K378 (6.1), C313-C382 (11.4), C313-C452 (8.3), C313-K494 (19.6), K339-K401 (8.4), 
K378-C382 (8.1), K378-C452 (11.6), K378-K494 (17.7), C382-C452 (15.4), C452-K461 (19.6), K461-
K463 (10.6).  These residue pairs imply the expected results from the cross-linking 





Figure 3.4 Expected cross-linking targets of rVGLUT1.  Amino acid residues Cys and 




3.3.3 In silico docking of L-glutamate 
An attempt was made to dock the natural substrate L-glutamate into rat VGLUT1 
(CPHmodels prediction) using the web-based program PatchDock.  When L-glutamate is 
docked (finds its most comfortable environment), the output shows in the protein model 
that amino acid residues H120 (TM2), Y319 (TM7) and H348 (TM8) of rVGLUT1 could be 
important in the binding of the endogenous substrate (Figure 3.5).  The docking result 
does not show the arginine and glutamate residues which were proposed for substrate 
binding as shown by recent mutational analysis (Juge 2006) and docking results by 
Almqvist and colleagues (2007).  Thus, our substrate-binding model may need further 
refinement or should be supported by experimental data. 
    
Figure 3.5 Putative binding sites of rVGLUT1 for L-glutamate.  The amino acid 
residues H120 (TM2), Y319 (TM7) and H348 (TM8) were predicted to be the key 




3.3.4 Multiple sequence alignments for homology modeling 
To date, the structural information of three membrane proteins (LacY, GlpT and 
EmrD) in the major facilitator superfamily (MFS) have been elucidated.  The established 
tertiary structures of these membrane proteins may serve as useful templates for building 
homology models of VGLUTs.  Sequence alignment is a critical step in building VGLUT 
homology models.  An amino acid substitution matrix needs to be evaluated and carefully 
chosen for performing sequence alignments.  Different amino acid substitution matrices 
were employed to generate multiple sequence alignments (MSA) of LacY, GlpT, EmrD 
and rVGLUT1 by ClustalW algorithm (Appendix G).  The MSA performance was 
evaluated by the transmembrane alignment scores (TmA, the number of alignment 
positions assigned as transmembrane regions for LacY, GlpT and EmrD).  The 
alignments (Appendix G) show that the amino acid substitution matrices of PAM 250 
(TmA 168), Wimley-White hydrophobicity (TmA 166) and transmembrane-propensity 
values (TmA 164) appear to be applicable to build the homology model of VGLUTs. 
To build a better homology model, the sequence alignment could be improved by 
employing a specific amino acid substitution matrix.  The amino acid substitution matrix 
generated by genetic algorithm-based optimization of hydrophobicity (Zviling 2005) was 
presumed to have the highest transmembrane alignment scores. So was the one generated 
by the transmembrane-propensity values.  But both of them failed to be a better matrix 
than PAM 250, according to transmembrane alignment scores.  The evaluation of 
sequence alignments for membrane proteins may be improved as the database size of 
structure-known membrane protein increases in the future. 
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3.3.5 Hydrophobicity Analysis 
Since Kyte and Doolittle (1982) proposed a hydropathy scale based on the free 
energy of transfer of each amino acid between organic solvent and water, the hydropathy 
plot with a sliding window of residues has been applied to the prediction of helical 
transmembrane domains.  Based on the analysis of hydropathy plots, Ni and colleagues 
(1994) predicted that VGLUT1 might have 6-8 transmembrane domains (Figure 3.6) and 
several putative glycosylation (N92 and N93) and phosphorylation sites (T96, S265, S267, 





Figure 3.6 An early transmembrane model of VGLUT1 (Ni, 1994).  Putative 
transmembrane segments: 68-87, 144-164, 210-229, 237-255, 337-357 and 
436-455. 
 
Using hydrophobicity values to predict the transmembrane segments is an old-
fashioned method, but still useful when biological knowledge about the folding 
Glycosylation sites
,   Phosphorylation sites 
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transmembrane proteins is limited.  Hydropathy scalograms with a series of sliding 
windows of amino acid residues indicate that rVGLUT1 may have 10-12 transmembrane 
segments (Figure 3.7).  As the sliding window increases, the hydropathy score of an 
amino acid in the rVGLUT1 is gradually smoothed by the hydropathy values of amino 
acids in its vicinity.  The scalogram presents the change of hydropathy density with an 




Figure 3.7 Hydropathy scalograms of rVGLUT1. A: Kyte-Doolittle scale; B: Wimley-
White scale; C: transmembrane-propensity scales.  The areas with high 
scores (in yellow to red) indicate the possibility of transmembrane domains 
(labeled as TM). 
 
3.3.6 Naïve consensus method of transmembrane predictions 
By submitting the rVGLUT1 protein sequence to different web-based programs, 
the outputs (Appendix C) show that rVGLUT1 can contain 9 to 14 transmembrane 
TM                   TM  TM         TM  TM              TM      TM          TM          TM    TM  
TM           TM   TM  TM        TM  TM              TM      TM              TM     TM    TM  
TM          TM   TM  TM         TM  TM               TM      TM      TM   TM     TM    TM  
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segments (Figure 3.8).  After combining these predictions through the in-house program 
(Chao 2004), the prediction converged to an assignment of 12 transmembrane segments 
(Figure 3.9).  The transmembrane prediction (TmP) score is the sum of transmembrane 
predictions at an amino acid residue.  A position with a TmP score more than 4 was 
arbitrarily assigned to a transmembrane region.  In this transmembrane prediction, TM4 
and TM9 are relatively shorter than the other transmembrane segments.  They could be 
reentries or partially incorporated in the membrane bilayer.  This prediction approach 
method is intuitively easy but needs further testing with a training set, and other 
membrane protein examples. 
 
 
Figure 3.8 Transmembrane predictions of rVGLUT1 by web-based programs.  A 
transmembrane region was assigned if its transmembrane prediction score is 





Figure 3.9 Predicted transmembrane topology of rVGLUT1 by naïve consensus 
method.  N-terminus: 1-62, TM1: 63-90, TM2: 116-138, TM3: 145-167, 
TM4: 169-179, TM5: 206-229, TM6: 233-257, TM7: 299-323, TM8: 340-
360, TM9: 389-399, TM10: 402-423, TM11: 436-459, TM12: 470-490, C-
terminus: 491-560. Candidate targets for chemical modification, amino 




3.3.7 Consensus method for transmembrane helix prediction (CoMTraP) 
To improve the consensus method for transmembrane prediction, the program 
CoMTraP was developed with the algorithm based on a consensus of transmembrane 
predictions from the web-based programs and a cut-off value to determine a specific 
transmembrane position.  The computational procedures include: (1) collection of 
transmembrane predictions of structure-known transporter proteins from web-based 
transmembrane prediction programs, (2) evaluation of the prediction accuracy by 
segment-based measures (Zemla 1999) and Matthews correlation index (CT, Matthews 
1975), (3) selection of most accurate web-based prediction programs to reduce 
computational cost, (4) combinations of prediction methods and cut-off values, (5) 
evaluation of the prediction accuracy of the combinations by segment-based measures 
and CT, and (6) selection of the combinations with highest prediction accuracy for the 
transmembrane prediction of the target protein (rVGLUT1). 
The prediction accuracy resulted in 16 prediction programs with higher accuracy.  
They are DAS-TMfilter, HMM-TM, HMMTOP, MEMSAT, MINNOU, PRED-TMR2, 
SMART, SOSUI, SPLIT, TMHMM, Tmpred, TopPred, TSEG, waveTM, SVMtop, and 
ZPRED (Table 3.3) that were selected for rVGLUT1 topology prediction using CoMTraP.  
The program CoMTraP resulted in the optimized prediction combination with the cut-off 
value set at 4 (sum of positive transmembrane predictions).  When evaluated with six 
structure-known proteins, the combination of THMMTM, HMMTOP, MINNOU, 
SMART, SVMtop and ZPRED have prediction accuracy at 0.6446 which is higher than 
any of the web-based programs.  The transmembrane helix prediction of VGLUT1 
obtained from CoMTraP is shown in Figure 3.10.  The length of putative TM4 is shorter 
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than the others.  This prediction is similar to that of the naïve method transmembrane 
prediction (Figure 3.9) or HMMTOP which is considered as the best transmembrane 
prediction program presently available (Table 3.4). 
While testing this current version of CoMTraP, only six proteins were included 
for computation.  It is possible to improve the prediction accuracy by employing more 
structure-known membrane proteins for evaluation of the prediction combinations.  Still, 
sequence homology is the major consideration in the future.  Moreover, computations 
with a big training set will be time-consuming and impractical. 
In the CoMTraP-predicted transmembrane model, all the 15 lysine residues are 
located in or close to the extra-membrane regions with an asymmetric distribution (K10, 
K25, K140, K196, K272, K283, K290, K378, K494 and K507 on one side; K106, K339, K401, K461 
and K463 on the other side).  The ε-amine (-NH2) group of a lysine residue is a candidate 
target for chemical modification and the residue is a site of tryptic cleavage.  With this 
feature, the transmembrane model can be validated and improved by experiments such as 
MS analysis with cross-linking or enzymatic cleavage, to provide low-resolution 




Table 3.3 Prediction accuracy of web-based transmembrane predictions 
Prediction Method Ranking Average of Matthews correlation indices 
BPROMPT 21 0.3957 
DAS 19 0.4196 
DAS-Tmfilter 16 0.4666 
HMM-TM 7 0.5574 
HMMTOP 3 0.5834 
MEMSAT 5 0.5712 
MINNOU 12 0.5322 
PHDhtm 18 0.4336 
PRED-TMR2 9 0.5395 
SMART 6 0.5586 
SOSUI 14 0.4987 
SPLIT 10 0.5326 
SVMtm 20 0.4008 
TMAP 22 0.3415 
TMHMM 4 0.5743 
Tmpred 11 0.5325 
TopPred 13 0.5100 
TSEG 17 0.4432 
WaveTM 15 0.4864 
SVMtop 8 0.5477 
ZPRED 2 0.6167 
CoMTraP 1 0.6446 
# The prediction accuracy was evaluated by Matthews correlation indices.  CoMTraP 





Figure 3.10 Predicted transmembrane topology of rVGLUT1 by CoMTraP.  N-
Terminus: 1-65, TM1: 66-88, TM2: 118-137, TM3: 145-163, TM4: 172-183, 
TM5: 210-229, TM6: 235-255, TM7: 302-323, TM8: 340-360, TM9: 379-
396, TM10: 402-424, TM11: 436-458, TM12: 471-489, C-terminus: 490-
560.  Candidate cleavage sites of trypsin, amino acid residue arginine (R) 






Table 3.4 Comparison of transmembrane predictions 
 Naïve HMMTOP CoMTraP 
TM1 063-090 067-091 066-088 
TM2 116-138 118-137 118-137 
TM3 145-167 146-165 145-163 
TM4 169-179* 170-189 172-183* 
TM5 206-229 210-229 210-229 
TM6 233-257 234-257 235-255 
TM7 299-323 299-323 302-323 
TM8 340-360 340-358 340-360 
TM9 389-399* 379-398 379-396 
TM10 402-423 403-422 402-424 
TM11 436-459 435-458 436-458 
TM12 470-490 471-490 471-489 
* The transmembrane segments are shorter than the 
length of 19 amino acids.  They could be reentries or 
partially incorporated in the membrane bilayer. 
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CHAPTER 4: FUNCTIONAL AND STRUCTURAL ANALYSIS OF VGLUT 




The complexity of biological membranes makes it complicated to study VGLUT 
structure in situ.  For this reason, incorporation of purified VGLUT into an artificial 
membrane (proteoliposome system) is not only a useful step but a critical one in studying 
the function and structure of VGLUT.  Fortunately, successful efforts have produced 
high-quality proteoliposomes (Rigaud 2002).  The basic procedures may include: (1) 
preparation of pure liposomes (using mechanical means, freeze-thawing, organic 
solvents, or detergents), (2) extraction and purification of membrane proteins from native 
membranes with proper solubilizing detergent concentrations, (3) reconstitution of 
membrane proteins with liposomes to form lipid-protein-detergent and lipid-detergent 
micelles, and (4) removal of detergent and further purification (Rigaud 2003).  Based on 
the lipid composition of adult rat brain synaptic vesicles (Morgan 1973), artificial 
synaptic vesicles could be prepared to reconstitute VGLUT protein. 
In the proteoliposome reconstitution with proton ATPase, glutamate uptake 
properties of VGLUT should be similar to the intact system (Maycox 1988; Juge 2006).  
The proton electrochemical gradient is a key component to drive glutamate uptake (Tabb 
1992).  It could be artificially established by manipulating the pH value of the 
proteoliposome interior by adding the appropriate ionophore and buffer solutions (Figure 
4.1).  Functional reconstitution into proteoliposomes allows better control of vesicular 
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glutamate uptake system, and thus enables us to simplify the working model.  This 
system allows us to advance a better understanding of functional and structural 
information of VGLUTs and could be applied to studies of other vesicular transporter 
proteins such as vesicular acetylcholine transporter (VAChT), vesicular GABA 
transporter (VGAT) and vesicular monoamine transporter (VMAT). 
To set up a simple system for functional test and mass spectral analysis, 
recombinant rVGLUT1 was isolated from the transformed Pichia pastoris, purified by 




Figure 4.1 Model for glutamate uptake in the proteoliposome system.  An ionophore is 





4.2 Materials and Methods 
 
4.2.1 Materials 
Chemicals were obtained from Sigma (St. Louis, MO) unless otherwise stated.  
Bio-Beads SM-2 adsorbent was obtained from Bio-Rad (Hercules, CA).  Sequencing-
grade modified trypsin was obtained from Promega (Madison, WI).  Formic acid (98%) 
was obtained from EM Scientific (Carson City, NV).  The solvents, acetonitrile and 
isopropanol, were both 99% and used without further purification.  Peptide calibration 
standards were obtained from Bruker Instruments (Billerica, MA). 
 
4.2.2 Reconstitution into proteoliposomes 
Reverse-phase method.  Proteoliposomes were prepared by the method 
published previously (Rigaud 2003).  Briefly, pure liposomes were prepared by mixing 
2.0 mg of phosphatidylcholine, 1.4 mg of phosphatidylethanolamine, 0.5 mg of 
phosphatidylserine and 1.1 mg of cholesterol in chloroform.  The chloroform was 
removed from the lipid solution by rotary evaporation.  Lipidic film was dissolved by the 
addition of 0.300 ml of diethyl ether and 0.100 ml of the reconstitution buffer (140 mM 
potassium gluconate) with or without 1 µM of acridine orange by vortexing for 5 min.  
Organic solvent was removed by rotary evaporation, and the liposome suspension was 
diluted with additional 1.00 ml of the reconstitution buffer.  The suspension was then 
extruded through 0.4- and 0.2-µm pore size polycarbonate filters (Whatman, Florham 
Park, NJ) three times.  TCA-precipitated VGLUT1 protein (10 µg dissolved in 50 µl of 
1% DDM) was added to the liposome solution and the mixture was incubated at room 
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temperature for 1 h and then at 4°C overnight.  The detergent (DDM) was removed by 
Bio-Beads SM-2 adsorbent.  VGLUT1 proteoliposomes were either stored at 4°C or 
concentrated by centrifugation at 36,668 g at 4 °C for 3 h. 
Freeze-thaw method.  A lipid-detergent mixture containing 121 mM K2SO4, 
1.2% (wt/vol) sodium cholate hydrate and 2.0% (wt/vol) asolectin was passed through a 
Sephadex G-50 column.  The fractions were collected and frozen at –80°C for 2 h or 
overnight.  After thawing, the liposomes were harvested by centrifugation at 20,000 g for 
60 min at 4°C, and resuspended in 2 volumes of the solution containing 121 mM K2SO4, 
2% CHAPS and 5% sucrose.  TCA-precipitated VGLUT1 protein was dissolved in the 
same solution to make a concentration of 2 mg/ml, and mixed with 1 volume of the 
liposome solution by gentle shaking at 4°C overnight.  The VGLUT1 proteoliposomes 
were further purified by a Sephadex G-50 column and Bio-Beads SM-2. 
 
4.2.3 Functional test of VGLUT1 proteoliposomes 
The ability of VGLUT1 proteoliposomes to generate a proton gradient with 
nigericin was determined by monitoring the quenching of acridine orange fluorescence.  
Glutamate uptake of VGLUT1 proteoliposomes was performed by incubation in 10 mM 
HEPES buffer (pH 7.4) containing 300 mM sucrose, 8 mM MgCl2 and 5 µM nigericin for 
5 min at 30°C.  Uptake was initiated by the addition of 250 mM 3H-L-glutamate.  Uptake 
was terminated after 90 s by rapid filtration onto 0.45 mm filters (Millipore, Billerica, 
MA) under vacuum and the addition of ice cold 150 mM KCl.  The radioactivity retained 
on the filters was determined by liquid scintillation counting.  
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4.2.4 Protein digestion 
For VGLUT1 proteoliposomes and TCA-purified VGLUT1 protein, the sample 
was dissolved or suspended in 50 mM ammonium bicarbonate (pH 8.0) to make the 
protein concentration 1 mg/ml.  After digestion with trypsin (0.05 mg/ml) 37ºC for 3 h, 
the sample was then dried by vacuum centrifuge and reconstituted for MS analysis. 
 
4.2.5 MALDI-TOF MS analysis 
Samples were reconstituted in 50% (vol/vol) acetonitrile in 0.1% (vol/vol) 
TFA/H2O.  Aliquots of the reconstituted solution were mixed 1:1 with α-cyano-4-
hydroxycinnamic acid (CHCA), spotted on the targeting plate and analyzed by the 
MALDI-TOF mass spectrometer (ABI Voyager DE STR, Applied Biosystems, Foster 
City, CA) with linear or reflectron mode.  The mass spectra were processed by Data 
Explorer (Applied Biosystems, Foster City, CA) and peptide mass values from the digests 
of VGLUT1 protein were processed by the daemon version of MASCOT (Perkins et al. 
1999), Protein Prospector (Clauser et al. 1999) or FINDMOD (Wilkins et al. 1999). 
 
4.2.6 NanoLC/Q-TOF MS analysis 
Samples were reconstituted in either 5% or 50% (vol/vol) acetonitrile in 0.1% 
(vol/vol) TFA/H2O.  The reconstituted solution was analyzed using nanoscale liquid 
chromatography/quadrupole-time of flight mass spectrometer (NanoAcquity UPLC/Q-
TOF MS, Waters, Milford, MA) equipped with a reverse-phase column (nanoACQUITY 
UPLC Columns, Waters, Milford, MA) with a gradient solvent system composed of 
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acetonitrile and 0.1% (vol/vol) formic acid.  Data were processed by ProteinLynx 




4.3 Results and Discussion 
 
4.3.1 Functional analysis of rVGLUT1 proteoliposomes 
Initial experiments of rVGLUT1 proteoliposomes were carried out by the reverse-
phase preparation.  When monitored by a fluorescence detector (Hitachi F-2000 
Fluorescence Spectrotometer, excitation wavelength at 490 nm and emission at 520 nm), 
the acridine orange encapsulated in the liposome did not show a significant leak within 
the first minute and the integrity of the proteoliposome was validated (Figure 4.2). 
 
 
Figure 4.2 Proteoliposome integrity test by monitor of fluorescence intensity.  Acridine 
orange (3 µM) was incorporated in the proteoliposomes. 
 
Since the reverse-phase preparation is time-consuming, the freeze-thaw 
preparation has been developed and improved.  By this method, a pH gradient 
(acidification) is generated with nigericin (ionophore) in the VGLUT1 proteoliposome 
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system.  The fluorescence quench observed in the proteoliposomes is less than that in rat 
synaptic vesicles (Figure 4.3). 
 
 
Figure 4.3 Acidification of rVGLUT1 proteoliposomes.  Rat synaptic vesicles and 
proteoliposomes were suspended in 5 mM HEPES buffer (pH 7.4) 
containing 265 mM sucrose and 3 µM acridine orange.  Acidification was 
generated by addition of 1mM ATP for the rat synaptic vesicles and 5 µM 
nigericin for the proteoliposomes.  The liposomes were disrupted when 




The L-glutamate uptake assay showed that the recombinant VGLUT1 protein in 
the liposomes was able to mediate the accumulation of glutamate in the proteoliposomes, 
but the uptake activity was only 7.19% of activity observed in rat synaptic vesicles over 
the period of 5 min (Figure 4.4).  Several factors could account for the low uptake, 
including: (1) incorrect folding of VGLUT1 protein in the proteoliposomes, (2) protein 
aggregation during the freeze-thaw process of reconstitution into liposomes, (3) inactivity 
of VGLUT1 protein due to an insufficient proton electrochemical gradient, and (4) the 
suitability of the proteoliposome preparation. 
 
 
Figure 4.4 L-Glutamate uptake assay.  1: Rat synaptic vesicles; 2: rat synaptic vesicles 
with 5 µM Congo red (glutamate uptake inhibitor); 3: VGLUT1 
proteoliposome; 4: liposome without VGLUT1 protein; 5: VGLUT1 
proteoliposome with 5 µM Congo red.  The error bars indicate the standard 
deviations of 4 samples.   The relative glutamate uptake of the VGLUT1 
proteoliposomes (3) is statistically significant (P<0.05) from that of the 




Several buffer systems were employed to optimize the buffer for preparation of 
proteoliposomes.  Because nigericin is a proton-potassium ionophore, the liposomes 
containing LiCl or NaCl did not show a significant fluorescence quench (acidification).  
Although non-buffered solutions generate more acidification, when different isosmotic 
solutions were tested, potassium sulfate solution showed the best ability to acidify the 
liposomes (Figure 4.5) probably because of the higher potassium concentration in the 
liposomes than that of KCl liposomes. 
With the potassium sulfate buffer, rVGLUT1 proteoliposomes were prepared and 
tested for its acidification (Figure 4.6).  A fluorescence quench occurred during the initial 
incubation in the buffer.  After adding nigericin (5 nM), the fluorescence intensity was 
minimized but gradually increased.  Afterwards, the addition of a higher concentration of 
nigericin (5 µM) did not reduce fluorescence intensity.  It is possible that the proton-
potassium exchange occurred without nigericin and the dynamic equilibrium was mostly 






































+ nigericin + Triton X-100
 
Figure 4.5 Comparison of acidification ability of different isosmotic solutions.  Two ml 
of 3 µM acridine orange in 265 mM sucrose was put into a cuvette with a 
stir bar for fluorescence measurement.  Liposomes (20 µl) were added to the 
cuvette at 300 sec, followed by the addition of 0.5 µM nigericin at 600 sec.  
Acidification was generated when adding 5 µM nigericin.  The liposomes 































+ 0.025% Triton X-100
+ 5 nM nigericin
 
Figure 4.6 Proton pumping ability of VGLUT1 proteoliposomes.  The proteoliposomes 
were prepared in 121 mM K2SO4 and tested in 5 mM HEPES buffer (pH 7.4) 
containing 265 mM sucrose and 3 µM acridine orange.  Acidification was 
generated when adding nigericin.  A higher concentration of nigericin did 
not further quench the fluorescence.  The proteoliposomes were disrupted 
when adding 0.025% (vol/vol) Triton X-100. 
 
The influence of sulfate on the glutamate uptake function of VGLUT1 protein is 
unknown.  Formulations of proteoliposomes may need to be further modified to evaluate 
the activity of VGLUT1 protein.  To transport glutamate molecules into vesicles, 
functional VGLUT and other facilitating components such as ATPase and other unknown 
proteins may be needed.  The function of the recombinant VGLUT1 protein remains to 
be determined. 
+ 5 µM nigericin 
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4.3.2 Structural analysis of rVGLUT1 proteoliposomes 
Based on the CoMTraP transmembrane model (Figure 3.11), without any organic 
solvent, trypsin would tend to cleave only the C-terminal to arginine and lysine residues 
due to the poor accessibility of hydrophobic transmembrane regions.  If rVGLUT1 
protein reconstituted in proteoliposome follows the CoMTraP transmembrane model, the 
nontransmembrane segments inside the lumen of the proteoliposome would be 
inaccessible for proteolytic enzymes.  Therefore, only the cleavage sites on the surface of 
the proteoliposome would be available for trypsin to cleave. 
With trypsin digestion, MALDI-TOF and NanoLC/Q-TOF MS analysis identified 
peptides from the rVGLUT1 reconstituted into proteoliposomes.  No organic solvents 
were added in the protein digestion to prevent rVGLUT1 proteoliposomes from 
disrupting.  Not all the transmembrane peptides were identified in theVGLUT1 trypsin 
digest.  This may be due to the inefficient digestion of rVGLUT1 protein in the buffer 
without organic solvent or the poor ionization of resulting peptides.  The mass spectral 
analysis of rVGLUT1 protein and proteoliposomes shows that no proteolytic cleavage 
sites were identified within the putative transmembranous regions (Table 4.1, Figure 4.7 
and 4.8).  Trypsin cleaved both the nontransmembrane sides in the denatured rVGLUT1 
protein but not the luminal side of the proteoliposome.  In rVGLUT1 proteoliposomes, 
trypsin cleavage sites at the N-terminus (K10, R14, and K25), loop 4 (K196 and R205), loop 8 
(K378), loop 10 (R432) and C-terminus (R558 and R569) were detected.  The results indicate 
that the trypsin was able to cut its target amino acid residues (arginine and lysine) only on 
the outer surface of the rVGLUT1 proteoliposomes.  The enzyme accessibility to the 
hydrophobic regions/membrane could determine the structural conformation of 
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rVGLUT1 protein in proteoliposomes.  Despite the pharmacological function, the mass 
spectral data support the rVGLUT1 transmembrane model (Figure 3.11).  Further 
experiments such as cross-linking reactions of the proteoliposomes would provide more 




Table 4.1 Mass spectral analysis of rVGLUT1 denatured protein and proteoliposomes 
Sample Peptide position m/z observed* Cleavage region Detection method 
026 – 047 2425.63 N-Terminus 
146 – 166 2180.62 Tm3, L3 
167 – 203 4195.11 L3, Tm4, L4 
272 – 290 2109.17 L6 
367 – 377 1334.26 L8 
367 – 401 3891.81 L8 
379 – 432 5596.70 Tm9, L9, Tm10, L10 
433 – 463 3150.90 L10, Tm110, L11 
559 – 587 3351.39 C-Terminus 
MALDI-TOF 
015 – 021 824.93 N-Terminus 
197 – 203 433.362+ L4 




559 – 569 677.032+ C-Terminus 
Q-TOF 
002 – 010 1269.12 N-Terminus 
019 – 025 909.13 N-Terminus 
369 – 377 1059.24 L8 
379 – 432 5600.63 Tm9, L9, Tm10, L10 
559 – 569 1243.37 C-Terminus 
MALDI-TOF 
015 – 025 654.132+ N-Terminus 




559 – 569 677.032+ C-Terminus 
Q-TOF 






Figure 4.7 Analysis of denatured rVGLUT1 protein.  Tryptic peptides identified by MALDI-TOF (marked in gray) and NanoLC/Q-





Figure 4.8 Analysis of VGLUT1 proteoliposomes.  Tryptic peptides identified by MALDI-TOF (marked in gray) and NanoLC/Q-
TOF (marked in purple) mass spectrometry are labeled with the protein sequence position.
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CHAPTER 5: SUMMARY 
 
Rat VGLUT1 (rVGLUT1) protein was successfully cloned and expressed in 
Pichia pastoris strain X-33.  The yeast genome DNA was confirmed by polymerase chain 
reaction.  His6-tagged rVGLUT1 protein was isolated form the yeast transformant by 
either soft-lysis or glass-bead method, purified by immobilized metal ion affinity 
chromatography (IMAC) with optimized procedures, and identified by immunodetection 
and its sequence information and overall coverage map were elucidated by mass 
spectrometry.  The rVGLUT1 overexpression system provides a source of rVGLUT1 
protein for functional and structural analysis. 
To test its uptake function, the recombinant rVGLUT1 protein was reconstituted 
in proteoliposome for functional and structural analysis.  The acidification of rVGLUT1 
proteoliposomes was confirmed by a pH-sensitive fluorescent dye, acridine orange.  
Preliminary glutamate uptake tests show slight L-glutamate uptake activity of the 
proteoliposomes; however, attempts in modifying the preparation of rVGLUT1 
proteoliposomes were made but failed to improve the glutamate uptake activity. 
To propose a topology hypothesis of rVGLUT1, the structural information was 
computationally deduced from its protein sequence text.  Homology and transmembrane 
models were built by web-based and in-house programs.  Both of the models show that 
the rVGLUT1 protein has 12-transmembrane domains with a structural symmetric center 
between transmembrane (TM) 6 and 7.  The in silico docking result indicates three 




Despite the functional identity, the mass spectral analysis shows asymmetrical 
tryptic cleavages of rVGLUT1 proteoliposomes – only on the outside surface of the 
proteoliposomes.  The results indicate the orientation of N- and C-terminus, loop 4, 8 and 





CHAPTER 6: CONCLUSION 
 
Rat VGLUT1 protein overexpressed in Pichia pastoris provides a convenient 
protein source to prepare the proteoliposomes for functional and structural analysis.  The 
pharmacological test of the recombinant VGLUT1 protein shows slight L-glutamate 
uptake.  Experimental parameters for the protein reconstitution need to be further 
optimized. 
Structural features of VGLUT protein are still unclear.  To hypothesize structural 
models to test, an attempt was made to build homology and transmembrane models with 
the sequence text of VGLUT protein.  It appears to be a naïve approach to generate a 
reliable model based on the limited understanding of membrane protein.  An early 
topology model proposed by Thompson (2002) shows 10 transmembrane domains 
(Figure 6.1).  Later, the X-crystal structures of GlpT, LacY and EmrD were published.  
With the database of structure-known membrane protein and the improvement in 
computational technology, the putative topology of VGLUT protein changed to have 12 
transmembrane domains.  Although minor discrepancy was found between the homology 
(CPHmodels) and transmembrane (CoMTraP) models, both of them show 12-
transmembrane domains (Figure 6.2). 
The 12-transmembrane topology of VGLUT1 protein is consistent with previous 
publications (Juge 2006; Jung 2006; Almqvist 2007).  The positive-inside rule (von 
Heijne 1986) and the glycine-outside rule (Jin 2008) might not be applicable to the 
topology of VGLUT1 protein.  The current algorithms of transmembrane predictions are 
based on physicochemical properties of amino acids (e.g. hydropathy, polarity bulkiness, 
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electronic effects and helicity), statistical propensity (e.g. Chou and Fasman method), 
spectral transformation (e.g. Fourier and wavelet transformation) or machine learning 
(e.g. hidden Markov model and support vector machine).  The prediction accuracy varies 
depending on the database and indicators for evaluation. 
 
 
Figure 6.1 The topology model of VGLUT protein by the beginning-end calculation.  
Adapted from Thompson (2002). 
 
The major obstacle of transmembrane prediction is that the biosynthesis of 
vesicular proteins is not clear and the structure-known membrane protein database is still 
in its infancy.  Even though it seemed impossible to have ideal prediction methods for 
VGLUT1 protein, our in-house CoMTraP method appears to be a proper approach for 






Figure 6.2 Comparison of the homology and transmembrane models.  The predicted 
transmembrane segments are marked in color. 
 
Mass spectral analysis of denatured VGLUT1 protein was performed with 100% 
sequence coverage using a combination of cleavage methods.  The enzyme accessibility 
of cleavage sites of VGLUT1 protein implies that the hydrophobicity value is a 
transmembrane discriminant.  Although the pharmacological function of the recombinant 
VGLUT1 protein in proteoliposomes remains to be defined, MS analytical results support 
the predicted VGLUT1 topology of 12-transmembrane domains. 
For the future studies, further experiments need to be done to confirm the results.  
These include optimizing the preparation of VGLUT proteoliposomes and chemical 
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Appendix A. Transmembrane segments of structure-determined transport proteins for 
generating the transmembrane-propensity scale.  The structural 
information was obtained from the UniProtKB/Swiss-Prot database 
(http://www.ebi.ac.uk/swissprot/). 
AcrB multidrug transporter (E. coli), ACRB_ECOLI P31224: 11-29, 331-356, 367-386, 
395-421. 
Aquaporin 1 (bovine), AQP1_BOVIN P47865: 10-34, 51-68, 79-88, 93-117, 143-158, 
170-187, 194-204, 216-230. 
BtuCD ABC transporter, BtuC subunit, BTUC_ECO57 Q8X4L7: 2-32, 47-81, 93-107, 
114-138, 142-166, 191-206, 229-249, 258-267, 272-296, 305-324. 
Ca ATPase, SR (rabbit), ATA1_RABIT P04191: 48-80, 89-119, 247-274, 289-307, 739-
779, 788-809, 830-852, 893-912, 930-950, 964-986. 
EmrE (Escherichia coli), EMRE_ECOLI P23895: 4-22, 33-53, 57-82, 84-106. 
F1F0 ATPsynthase Subunit C (E. coli), ATPL_ECOLI P00844: 2-39, 47-77. 
FecA (E. coli), FECA_ECOLI P13036: 223-235, 242-254, 258-269, 279-289, 296-305, 
338-346, 352-362, 382-393, 402-413, 447-456, 460-470, 488-499, 505-515, 536-546, 
551-562, 582-592, 604-614, 634-643, 647-657, 681-692, 698-709, 732-741. 
FepA (E. coli), FEPA_ECOLI P05825: 154-164, 172-182, 187-197, 229-241, 245-255, 
283-293, 302-313, 343-356, 360-371, 408-419, 424-434, 441-451, 456-467, 505-517, 
521-532, 560-574, 578-589, 605-616, 619-628, 654-664, 669-679, 716-723. 
Ferric hydroxamate uptake receptor (E. coli), FHUA_ECOLI P06971: 160-168, 174-182, 
190-198, 213-221, 227-235, 280-288, 294-302, 355-363, 371-380, 432-441, 444-453, 
476-485, 489-497, 520-528, 533-541, 569-578, 581-589, 613-622, 628-637, 658-666, 
672-680, 706-714. 
Gamma-aminobutyrate transporter (E. coli), GABP_ECOLI P25527: 18-40, 42-63, 87-
109, 123-145, 158-180, 195-217, 244-266, 288-310, 333-356, 362-384, 398-420, 427-449. 
GlpT glycerol-3-phosphate transporter (E. coli), GLPT_ECOLI P08194: 20-57, 64-88, 
94-112, 121-147, 153-180, 190-207, 253-282, 288-316, 322-341, 347-374, 380-409, 415-
448. 
Glucose 6-PO4 translocase (human), G6PU_HUMAN O43826: 8-26, 78-107, 137-163, 
169-187, 220-239, 265-283, 303-320, 329-349, 367-388, 396-414. 
Glucose transporter type 1, erythrocyte/brain (Human): 13-33, 67-87, 96-116, 127-147, 
156-176, 186-206, 272-292, 308-328, 338-358, 372-392, 402-422, 430-450. 




High-affinity nickel transporter (A. eutrophus), HOXN_ALCEU P23516: 20-40, 52-72, 
95-115, 129-149, 200-220, 244-264, 270-290. 
His periplasmic permease. M protein (S. typhimurium), HISM_SALTY P02912: 20-57, 
68-85, 100-128, 159-182, 200-221. 
His periplasmic permease. Q protein (S. typhimurium), HISQ_SALTY P02913: 19-37, 
57-80, 92-109, 149-173, 192-215. 
LacY lactose permease, 3D structure (E. coli), LACY_ECOLI P02920: 6-34, 42-70, 75-
100, 104-136, 140-164, 166-186, 221-247, 254-276, 288-304, 312-340, 343-376, 378-399. 
maltose transport protein. malF (E.coli), MALF_ECOLI P02916: 17-36, 40-59, 67-92, 
276-306, 319-355, 370-392, 425-453, 484-506. 
maltose transport protein. malG (E. coli), MALG_ECOLI P07622: 18-37, 91-111, 124-
144, 160-177, 205-227, 263-281. 
MsbA ABC transporter (E. coli), MSBA_ECOLI P27299: 21-49, 63-99, 139-164, 168-
194, 253-273, 282-303. 
MsbA multidrug transporter (Vibrio cholera), Q9KQW9: 24-51, 65-91, 142-163, 166-192, 
251-273, 279-302. 
Na(+)/H(+) antiporter 1: 12-30, 59-85, 95-116, 121-143, 150-175, 182-200, 205-218, 
223-236, 247-271, 290-311, 327-350, 357-382. 
Na+/proline transporter (E. coli), PUTP_ECOLI P07117: 3-27, 40-67, 75-96, 124-150, 
161-184, 188-212, 229-256, 273-295, 321-349, 367-389, 394-421, 425-445, 447-470. 
Nramp (Escherichia coli), MNTH_ECOLI P77145: 20-38, 49-71, 92-114, 121-145, 156-
174, 195-219, 239-262, 281-302, 324-344, 351-371, 388-408. 
Oxalate:formate antiporter, OXLT_OXAFO Q51330: 16-36, 47-67, 83-103, 107-127, 
140-160, 171-191, 221-241, 249-269, 287-307, 310-330, 349-369, 377-397. 
sec61p (Saccharomyces cerevisiae), S61A_YEAST P32915: 33-55, 76-95, 120-141, 147-
167, 213-224, 241-260, 291-311, 362-381, 417-434, 438-459. 
Vitamin B12 receptor (E. coli), BTUB_ECOLI P06129: 137-145, 149-159, 164-175, 
197-209, 214-227, 243-257, 261-276, 289-305, 309-322, 334-348, 351-362, 366-380, 





Appendix B. Perl program code for generation of hydropathy scalograms. 





push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,0,255)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,3,252)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,6,249)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,9,246)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,12,243)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,15,240)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,18,237)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,21,234)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,24,231)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,27,228)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,30,225)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,33,222)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,36,219)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,39,216)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,42,213)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,45,210)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,48,207)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,51,204)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,54,201)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,57,198)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,60,195)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,63,192)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,66,189)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,72,183)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,75,180)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,78,177)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,81,174)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,84,171)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,87,168)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,90,165)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,93,162)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,96,159)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,99,156)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,102,153)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,105,150)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,108,147)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,111,144)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,114,141)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,117,138)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,120,135)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,123,132)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,126,129)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,129,126)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,132,123)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,135,120)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,138,117)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,141,114)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,144,111)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,147,108)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,150,105)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,156,99)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,159,96)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,162,93)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,165,90)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,168,87)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,171,84)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,174,81)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,177,78)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,180,75)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,183,72)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,186,69)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,189,66)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,192,63)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,195,60)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,198,57)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,201,54)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,204,51)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,207,48)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,210,45)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,213,42)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,216,39)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,219,36)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,222,33)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,225,30)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,228,27)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,231,24)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,234,21)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,240,15)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,243,12)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,246,9)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,249,6)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,252,3)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(0,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(3,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(6,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(9,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(12,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(15,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(18,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(21,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(24,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(27,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(30,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(33,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(36,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(39,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(42,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(45,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(48,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(51,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(54,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(57,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(60,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(63,255,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(69,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(72,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(75,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(78,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(81,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(84,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(87,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(90,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(93,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(96,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(99,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(102,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(105,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(108,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(111,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(114,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(117,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(120,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(123,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(126,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(129,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(132,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(135,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(138,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(141,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(144,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(147,255,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(153,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(156,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(159,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(162,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(165,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(168,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(171,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(174,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(177,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(180,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(183,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(186,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(189,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(192,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(195,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(198,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(201,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(204,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(207,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(210,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(213,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(216,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(219,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(222,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(225,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(228,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(231,255,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(237,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(240,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(243,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(246,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(249,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(252,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,255,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,252,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,249,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,246,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,243,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,240,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,237,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,234,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,231,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,228,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,225,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,222,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,219,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,216,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,213,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,210,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,207,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,204,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,201,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,198,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,195,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,189,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,186,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,183,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,180,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,177,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,174,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,171,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,168,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,165,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,162,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,159,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,156,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,153,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,150,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,147,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,144,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,141,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,138,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,135,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,132,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,129,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,126,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,123,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,120,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,117,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,114,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,111,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,105,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,102,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,99,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,96,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,93,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,90,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,87,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,84,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,81,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,78,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,75,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,72,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,69,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,66,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,63,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,60,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,57,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,54,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,51,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,48,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,45,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,42,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,39,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,36,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,33,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,30,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,27,0)></TD>"); 




push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,21,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,18,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,15,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,12,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,9,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,6,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,3,0)></TD>"); 
push (@my_color_code,"<TD vAlign=middle align=center width=1 
bgColor=rgb(255,0,0)></TD>"); 
 


















print OUTFILE "<P>Kyte-Doolittle Scale, Kyte and Doolittle, J Mol Biol 
157:105-132 (1982)</P><TABLE CELLSPACING=0 bgColor=rgb(255,255,255) 
BORDER=0 HEIGHT=88% WIDTH=10%><TBODY><TR>","\n"; 
generate_hydropathy_scalogram(); 
 





print OUTFILE "<P>Wimley-White Scale. Wimley and White, Nat Struct Biol 




# Helix-propensity scale, Chao CK, 2005 







print OUTFILE "<P>Helix-propensity scale. Chao CK. (2005)</P><TABLE 


































if ((($n+$m)>-1) && (($n+$m)<(scalar @helix_propensity))){ 
$this_total_hydorpathy_score=$this_total_hydorpathy_score+$helix_propen
sity[$n+$m]*$this_frequency; 










print OUTFILE $this_intensity; 
} 
print OUTFILE "</TR><TR>","\n"; 
} 
for ($n=0;$n<(length($protein_sequence));$n++){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(255,255,255)></TD>"; 
} 





print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(0,0,0)></TD>"; 
} else { 




print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<(length($protein_sequence));$n++){ 
if ((($n+1)/50)==int(($n+1)/50)){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(0,0,0)></TD>"; 
} else { 




print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<(length($protein_sequence));$n++){ 
if ((($n+1)/10)==int(($n+1)/10)){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(0,0,0)></TD>"; 
} else { 




print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<(length($protein_sequence));$n++){ 
if ((($n+1)/2)==int(($n+1)/2)){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(0,0,0)></TD>"; 
} else { 




print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<(length($protein_sequence));$n++){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(255,255,255)></TD>"; 
} 
print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<(length($protein_sequence));$n++){ 
print OUTFILE "<TD vAlign=middle align=center width=1 
bgColor=rgb(255,255,255)></TD>"; 
} 
print OUTFILE "</TR><TR>","\n"; 
for ($n=0;$n<256;$n++){ 
print OUTFILE $my_color_code[$n]; 
} 
print OUTFILE "</TR><TR>","\n"; 





Appendix C. Transmembrane prediction results from web-based programs. 
PROMPT: 65-76, 150-154, 172-178, 220-227, 241-255, 305-309, 345-357, 405-417, 
473-486. 
DAS: 64-90, 120-130, 147-159, 169-181, 216-229, 237-256, 302-312, 315-324, 341-358, 389-
397, 403-419, 436-440, 446-457, 471-488. 
HMMTOP: 67-91, 118-137, 146-165, 170-189, 210-229, 234-257, 299-323, 340-358, 
379-398, 403-422, 435-458, 471-490. 
MEMSAT: 63-79, 146-165, 206-229, 237-257, 304-323, 340-359, 402-422, 436-459, 
470-490. 
orienTM: 63-79, 118-138, 146-165, 210-229, 237-255, 304-323, 340-359, 403-422, 436-
456, 471-490. 
PHDhtm: 61-84, 122-138, 147-178, 214-255, 301-323, 346-360, 384-421, 440-450, 473-
489. 
PRED-TMR: 63-79, 118-138, 146-165, 210-229, 237-255, 304-323, 340-359, 403-422, 
436-456, 471-490. 
SMART: 69-91, 116-138, 145-167, 206-228, 233-255, 301-323, 340-362, 402-424, 436-
458. 
SOSUI: 63-85, 138-160, 163-185, 207-229, 238-260, 304-326, 338-360, 402-423, 470-
491. 
SPLIT: 56-92, 117-137, 139-164, 205-229, 233-257, 298-325, 340-362, 400-424, 431-
463, 469-490. 
TMAP: 60-88, 115-135, 151-179, 206-226, 235-255, 294-317, 337-365, 395-423, 461-
487. 
TMHMM: 69-91, 116-138, 145-167, 206-228, 233-255, 301-323, 340-362, 402-424, 
436-458, 468-490. 
TMpred: 63-88, 115-137, 146-165, 170-195, 210-229, 239-257, 298-319, 340-357, 402-
422, 436-459, 470-489. 
TopPred: 62-82, 118-138, 145-165, 209-229, 237-257, 297-317, 340-360, 379-399, 402-
422, 440-460, 470-490. 





Appendix D. Amino acid substitution matrices for sequence alignments 
# BLOSUM62 (Henikoff and Henikoff 1992) 
   A  R  N  D  C  Q  E  G  H  I  L  K  M  F  P  S  T  W  Y  V  B  Z  X  * 
A  4 -1 -2 -2  0 -1 -1  0 -2 -1 -1 -1 -1 -2 -1  1  0 -3 -2  0 -2 -1  0 -4  
R -1  5  0 -2 -3  1  0 -2  0 -3 -2  2 -1 -3 -2 -1 -1 -3 -2 -3 -1  0 -1 -4  
N -2  0  6  1 -3  0  0  0  1 -3 -3  0 -2 -3 -2  1  0 -4 -2 -3  3  0 -1 -4  
D -2 -2  1  6 -3  0  2 -1 -1 -3 -4 -1 -3 -3 -1  0 -1 -4 -3 -3  4  1 -1 -4  
C  0 -3 -3 -3  9 -3 -4 -3 -3 -1 -1 -3 -1 -2 -3 -1 -1 -2 -2 -1 -3 -3 -2 -4  
Q -1  1  0  0 -3  5  2 -2  0 -3 -2  1  0 -3 -1  0 -1 -2 -1 -2  0  3 -1 -4  
E -1  0  0  2 -4  2  5 -2  0 -3 -3  1 -2 -3 -1  0 -1 -3 -2 -2  1  4 -1 -4  
G  0 -2  0 -1 -3 -2 -2  6 -2 -4 -4 -2 -3 -3 -2  0 -2 -2 -3 -3 -1 -2 -1 -4  
H -2  0  1 -1 -3  0  0 -2  8 -3 -3 -1 -2 -1 -2 -1 -2 -2  2 -3  0  0 -1 -4  
I -1 -3 -3 -3 -1 -3 -3 -4 -3  4  2 -3  1  0 -3 -2 -1 -3 -1  3 -3 -3 -1 -4  
L -1 -2 -3 -4 -1 -2 -3 -4 -3  2  4 -2  2  0 -3 -2 -1 -2 -1  1 -4 -3 -1 -4  
K -1  2  0 -1 -3  1  1 -2 -1 -3 -2  5 -1 -3 -1  0 -1 -3 -2 -2  0  1 -1 -4  
M -1 -1 -2 -3 -1  0 -2 -3 -2  1  2 -1  5  0 -2 -1 -1 -1 -1  1 -3 -1 -1 -4  
F -2 -3 -3 -3 -2 -3 -3 -3 -1  0  0 -3  0  6 -4 -2 -2  1  3 -1 -3 -3 -1 -4  
P -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1 -2 -4  7 -1 -1 -4 -3 -2 -2 -1 -2 -4  
S  1 -1  1  0 -1  0  0  0 -1 -2 -2  0 -1 -2 -1  4  1 -3 -2 -2  0  0  0 -4  
T  0 -1  0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1  1  5 -2 -2  0 -1 -1  0 -4  
W -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2 -3 -1  1 -4 -3 -2 11  2 -3 -4 -3 -2 -4  
Y -2 -2 -2 -3 -2 -1 -2 -3  2 -1 -1 -2 -1  3 -3 -2 -2  2  7 -1 -3 -2 -1 -4  
V  0 -3 -3 -3 -1 -2 -2 -3 -3  3  1 -2  1 -1 -2 -2  0 -3 -1  4 -3 -2 -1 -4  
B -2 -1  3  4 -3  0  1 -1  0 -3 -4  0 -3 -3 -2  0 -1 -4 -3 -3  4  1 -1 -4  
Z -1  0  0  1 -3  3  4 -2  0 -3 -3  1 -1 -3 -1  0 -1 -3 -2 -2  1  4 -1 -4  
X  0 -1 -1 -1 -2 -1 -1 -1 -1 -1 -1 -1 -1 -1 -2  0  0 -2 -1 -1 -1 -1 -1 -4  
* -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4  1  
 
 
# Dayhoff Matrix (Dayhoff et al. 1978; Zintzaras and Kowald 1999) 
   A  R  N  D  C  Q  E  G  H  I  L  K  M  F  P  S  T  W  Y  V  B  Z  X  * 
A  2 -2  0  0 -2  0  0  1 -1 -1 -2 -1 -1 -4  1  1  1 -6 -3  0  0  0  0 -8 
R -2  6  0 -1 -4  1 -1 -3  2 -2 -3  3  0 -4  0  0 -1  2 -4 -2 -1  0 -1 -8 
N  0  0  2  2 -4  1  1  0  2 -2 -3  1 -2 -4 -1  1  0 -4 -2 -2  2  1  0 -8 
D  0 -1  2  4 -5  2  3  1  1 -2 -4  0 -3 -6 -1  0  0 -7 -4 -2  3  3 -1 -8 
C -2 -4 -4 -5 12 -5 -5 -3 -3 -2 -6 -5 -5 -4 -3  0 -2 -8  0 -2 -4 -5 -3 -8 
Q  0  1  1  2 -5  4  2 -1  3 -2 -2  1 -1 -5  0 -1 -1 -5 -4 -2  1  3 -1 -8 
E  0 -1  1  3 -5  2  4  0  1 -2 -3  0 -2 -5 -1  0  0 -7 -4 -2  3  3 -1 -8 
G  1 -3  0  1 -3 -1  0  5 -2 -3 -4 -2 -3 -5 -1  1  0 -7 -5 -1  0  0 -1 -8 
H -1  2  2  1 -3  3  1 -2  6 -2 -2  0 -2 -2  0 -1 -1 -3  0 -2  1  2 -1 -8 
I -1 -2 -2 -2 -2 -2 -2 -3 -2  5  2 -2  2  1 -2 -1  0 -5 -1  4 -2 -2 -1 -8 
L -2 -3 -3 -4 -6 -2 -3 -4 -2  2  6 -3  4  2 -3 -3 -2 -2 -1  2 -3 -3 -1 -8 
K -1  3  1  0 -5  1  0 -2  0 -2 -3  5  0 -5 -1  0  0 -3 -4 -2  1  0 -1 -8 
M -1  0 -2 -3 -5 -1 -2 -3 -2  2  4  0  6  0 -2 -2 -1 -4 -2  2 -2 -2 -1 -8 
F -4 -4 -4 -6 -4 -5 -5 -5 -2  1  2 -5  0  9 -5 -3 -3  0  7 -1 -4 -5 -2 -8 
P  1  0 -1 -1 -3  0 -1 -1  0 -2 -3 -1 -2 -5  6  1  0 -6 -5 -1 -1  0 -1 -8 
S  1  0  1  0  0 -1  0  1 -1 -1 -3  0 -2 -3  1  2  1 -2 -3 -1  0  0  0 -8 
T  1 -1  0  0 -2 -1  0  0 -1  0 -2  0 -1 -3  0  1  3 -5 -3  0  0 -1  0 -8 
W -6  2 -4 -7 -8 -5 -7 -7 -3 -5 -2 -3 -4  0 -6 -2 -5 17  0 -6 -5 -6 -4 -8 
Y -3 -4 -2 -4  0 -4 -4 -5  0 -1 -1 -4 -2  7 -5 -3 -3  0 10 -2 -3 -4 -2 -8 
V  0 -2 -2 -2 -2 -2 -2 -1 -2  4  2 -2  2 -1 -1 -1  0 -6 -2  4 -2 -2 -1 -8 
B  0 -1  2  3 -4  1  3  0  1 -2 -3  1 -2 -4 -1  0  0 -5 -3 -2  3  2 -1 -8 
Z  0  0  1  3 -5  3  3  0  2 -2 -3  0 -2 -5  0  0 -1 -6 -4 -2  2  3 -1 -8 
X  0 -1  0 -1 -3 -1 -1 -1 -1 -1 -1 -1 -1 -2 -1  0  0 -4 -2 -1 -1 -1 -1 -8 
* -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8  1 
 
 103
# PAM 250 (Dayhoff et al. 1978) 
   A  R  N  D  C  Q  E  G  H  I  L  K  M  F  P  S  T  W  Y  V  B  Z  X  * 
A  2 -2  0  0 -2  0  0  1 -1 -1 -2 -1 -1 -3  1  1  1 -6 -3  0  0  0  0 -8 
R -2  6  0 -1 -4  1 -1 -3  2 -2 -3  3  0 -4  0  0 -1  2 -4 -2 -1  0 -1 -8 
N  0  0  2  2 -4  1  1  0  2 -2 -3  1 -2 -3  0  1  0 -4 -2 -2  2  1  0 -8 
D  0 -1  2  4 -5  2  3  1  1 -2 -4  0 -3 -6 -1  0  0 -7 -4 -2  3  3 -1 -8 
C -2 -4 -4 -5 12 -5 -5 -3 -3 -2 -6 -5 -5 -4 -3  0 -2 -8  0 -2 -4 -5 -3 -8 
Q  0  1  1  2 -5  4  2 -1  3 -2 -2  1 -1 -5  0 -1 -1 -5 -4 -2  1  3 -1 -8 
E  0 -1  1  3 -5  2  4  0  1 -2 -3  0 -2 -5 -1  0  0 -7 -4 -2  3  3 -1 -8 
G  1 -3  0  1 -3 -1  0  5 -2 -3 -4 -2 -3 -5  0  1  0 -7 -5 -1  0  0 -1 -8 
H -1  2  2  1 -3  3  1 -2  6 -2 -2  0 -2 -2  0 -1 -1 -3  0 -2  1  2 -1 -8 
I -1 -2 -2 -2 -2 -2 -2 -3 -2  5  2 -2  2  1 -2 -1  0 -5 -1  4 -2 -2 -1 -8 
L -2 -3 -3 -4 -6 -2 -3 -4 -2  2  6 -3  4  2 -3 -3 -2 -2 -1  2 -3 -3 -1 -8 
K -1  3  1  0 -5  1  0 -2  0 -2 -3  5  0 -5 -1  0  0 -3 -4 -2  1  0 -1 -8 
M -1  0 -2 -3 -5 -1 -2 -3 -2  2  4  0  6  0 -2 -2 -1 -4 -2  2 -2 -2 -1 -8 
F -3 -4 -3 -6 -4 -5 -5 -5 -2  1  2 -5  0  9 -5 -3 -3  0  7 -1 -4 -5 -2 -8 
P  1  0  0 -1 -3  0 -1  0  0 -2 -3 -1 -2 -5  6  1  0 -6 -5 -1 -1  0 -1 -8 
S  1  0  1  0  0 -1  0  1 -1 -1 -3  0 -2 -3  1  2  1 -2 -3 -1  0  0  0 -8 
T  1 -1  0  0 -2 -1  0  0 -1  0 -2  0 -1 -3  0  1  3 -5 -3  0  0 -1  0 -8 
W -6  2 -4 -7 -8 -5 -7 -7 -3 -5 -2 -3 -4  0 -6 -2 -5 17  0 -6 -5 -6 -4 -8 
Y -3 -4 -2 -4  0 -4 -4 -5  0 -1 -1 -4 -2  7 -5 -3 -3  0 10 -2 -3 -4 -2 -8 
V  0 -2 -2 -2 -2 -2 -2 -1 -2  4  2 -2  2 -1 -1 -1  0 -6 -2  4 -2 -2 -1 -8 
B  0 -1  2  3 -4  1  3  0  1 -2 -3  1 -2 -4 -1  0  0 -5 -3 -2  3  2 -1 -8 
Z  0  0  1  3 -5  3  3  0  2 -2 -3  0 -2 -5  0  0 -1 -6 -4 -2  2  3 -1 -8 
X  0 -1  0 -1 -3 -1 -1 -1 -1 -1 -1 -1 -1 -2 -1  0  0 -4 -2 -1 -1 -1 -1 -8 
* -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8  1 
 
 
# Matrix derived from Kyte-Doolittle hydrophobicity scales (Kyte and Doolittle 1982) 
   A  C  D  E  F  G  H  I  K  L  M  N  P  Q  R  S  T  V  W  Y  * 
A  9  7 -2 -2  7  4 -1  3 -3  5  8 -2  2 -2 -4  3  4  4  3  2 -4 
C  7  9 -3 -3  8  3 -3  5 -4  6  7 -3  0 -3 -5  2  2  5  2  1 -5 
D -2 -3  9  9 -4  2  8 -7  8 -6 -2  9  5  9  7  3  3 -7  3  4  7 
E -2 -3  9  9 -4  2  8 -7  8 -6 -2  9  5  9  7  3  3 -7  3  4  7 
F  7  8 -4 -4  9  2 -3  5 -5  7  7 -4  0 -4 -6  1  2  6  1  0 -6 
G  4  3  2  2  2  9  3 -1  2  0  4  2  6  2  0  8  8 -1  8  7  0 
H -1 -3  8  8 -3  3  9 -7  7 -5 -2  8  5  8  6  4  4 -6  4  5  6 
I  3  5 -7 -7  5 -1 -7  9 -8  7  3 -7 -4 -7 -9 -2 -2  8 -2 -3 -9 
K -3 -4  8  8 -5  2  7 -8  9 -7 -3  8  4  8  7  2  2 -8  3  3  7 
L  5  6 -6 -6  7  0 -5  7 -7  9  5 -6 -2 -6 -8 -1  0  8 -1 -2 -8 
M  8  7 -2 -2  7  4 -2  3 -3  5  9 -2  2 -2 -4  3  3  4  3  2 -4 
N -2 -3  9  9 -4  2  8 -7  8 -6 -2  9  5  9  7  3  3 -7  3  4  7 
P  2  0  5  5  0  6  5 -4  4 -2  2  5  9  5  3  7  7 -3  7  8  3 
Q -2 -3  9  9 -4  2  8 -7  8 -6 -2  9  5  9  7  3  3 -7  3  4  7 
R -4 -5  7  7 -6  0  6 -9  7 -8 -4  7  3  7  9  1  1 -9  1  2  9 
S  3  2  3  3  1  8  4 -2  2 -1  3  3  7  3  1  9  8 -1  8  8  1 
T  4  2  3  3  2  8  4 -2  2  0  3  3  7  3  1  8  9 -1  8  7  1 
V  4  5 -7 -7  6 -1 -6  8 -8  8  4 -7 -3 -7 -9 -1 -1  9 -2 -2 -9 
W  3  2  3  3  1  8  4 -2  3 -1  3  3  7  3  1  8  8 -2  9  8  1 
Y  2  1  4  4  0  7  5 -3  3 -2  2  4  8  4  2  8  7 -2  8  9  2 




# Matrix derived from Wimley-White hydrophobicity scales (Wimley et al. 1996) 
   A  C  D  E  F  G  H  I  K  L  M  N  P  Q  R  S  T  V  W  Y  * 
A  9  7 -1 -1  2  6  3  3  1  3  5  7  7  8  4  8  8  5  0  5  0 
C  7  9 -3 -3  3  5  1  5  0  5  6  6  8  6  3  7  8  7  2  6  2 
D -1 -3  9  8 -8  1  4 -6  6 -7 -5  0 -2 -1  3 -1 -2 -4 -9 -5 -9 
E -1 -3  8  9 -8  1  4 -6  6 -7 -5  0 -2  0  3 -1 -2 -4 -9 -5 -9 
F  2  3 -8 -8  9  0 -4  7 -6  7  5  0  3  1 -3  2  2  5  7  5  7 
G  6  5  1  1  0  9  5  1  3  1  3  8  5  7  6  6  6  3 -2  3 -2 
H  3  1  4  4 -4  5  9 -2  7 -3 -1  4  2  4  7  3  2  0 -5 -1 -5 
I  3  5 -6 -6  7  1 -2  9 -4  8  7  2  5  3 -1  4  4  6  5  7  5 
K  1  0  6  6 -6  3  7 -4  9 -4 -2  2  0  2  5  1  0 -2 -7 -3 -7 
L  3  5 -7 -7  7  1 -3  8 -4  9  7  2  4  2 -1  3  4  6  6  7  6 
M  5  6 -5 -5  5  3 -1  7 -2  7  9  4  6  4  1  5  6  8  4  8  4 
N  7  6  0  0  0  8  4  2  2  2  4  9  6  8  5  7  7  4 -1  4 -1 
P  7  8 -2 -2  3  5  2  5  0  4  6  6  9  7  3  7  8  7  1  6  1 
Q  8  6 -1  0  1  7  4  3  2  2  4  8  7  9  5  8  7  5  0  4  0 
R  4  3  3  3 -3  6  7 -1  5 -1  1  5  3  5  9  4  4  1 -4  1 -4 
S  8  7 -1 -1  2  6  3  4  1  3  5  7  7  8  4  9  8  6  0  5  0 
T  8  8 -2 -2  2  6  2  4  0  4  6  7  8  7  4  8  9  6  1  5  1 
V  5  7 -4 -4  5  3  0  6 -2  6  8  4  7  5  1  6  6  9  3  8  3 
W  0  2 -9 -9  7 -2 -5  5 -7  6  4 -1  1  0 -4  0  1  3  9  4  9 
Y  5  6 -5 -5  5  3 -1  7 -3  7  8  4  6  4  1  5  5  8  4  9  4 
*  0  2 -9 -9  7 -2 -5  5 -7  6  4 -1  1  0 -4  0  1  3  9  4  0 
 
 
# Matrix derived from transmembrane-propensity values (Chao 2005) 
   A  C  D  E  F  G  H  I  K  L  M  N  P  Q  R  S  T  V  W  Y  * 
A  9  6 -2 -4  7  7  6  6 -4  8  7  1  1  1 -7  2  3  8  7  7 -7 
C  6  9 -5 -7  7  4  8  8 -7  6  7 -2 -2 -2 -9 -1  0  6  5  4 -9 
D -2 -5  9  6 -4  0 -4 -4  7 -2 -3  6  6  6  4  5  3 -2 -1 -1  4 
E -4 -7  6  9 -6 -3 -7 -6  8 -5 -5  4  4  4  6  2  1 -4 -3 -3  6 
F  7  7 -4 -6  9  5  8  8 -5  7  8 -1 -1 -1 -8  0  2  7  6  6 -8 
G  7  4  0 -3  5  9  4  5 -2  7  6  2  2  2 -5  4  5  7  8  8 -5 
H  6  8 -4 -7  8  4  9  8 -6  6  7 -2 -2 -2 -9  0  1  6  5  5 -9 
I  6  8 -4 -6  8  5  8  9 -6  7  7 -2 -1 -2 -9  0  1  6  5  5 -9 
K -4 -7  7  8 -5 -2 -6 -6  9 -4 -5  4  4  4  6  3  1 -4 -3 -3  6 
L  8  6 -2 -5  7  7  6  7 -4  9  8  0  0  0 -7  2  3  8  7  7 -7 
M  7  7 -3 -5  8  6  7  7 -5  8  9 -1  0 -1 -8  1  2  7  6  6 -8 
N  1 -2  6  4 -1  2 -2 -2  4  0 -1  9  8  9  1  7  6  1  2  2  1 
P  1 -2  6  4 -1  2 -2 -1  4  0  0  8  9  8  1  7  6  1  2  2  1 
Q  1 -2  6  4 -1  2 -2 -2  4  0 -1  9  8  9  1  7  6  1  2  2  1 
R -7 -9  4  6 -8 -5 -9 -9  6 -7 -8  1  1  1  9  0 -1 -7 -6 -5  9 
S  2 -1  5  2  0  4  0  0  3  2  1  7  7  7  0  9  7  2  3  3  0 
T  3  0  3  1  2  5  1  1  1  3  2  6  6  6 -1  7  9  3  4  5 -1 
V  8  6 -2 -4  7  7  6  6 -4  8  7  1  1  1 -7  2  3  9  7  7 -7 
W  7  5 -1 -3  6  8  5  5 -3  7  6  2  2  2 -6  3  4  7  9  8 -6 
Y  7  4 -1 -3  6  8  5  5 -3  7  6  2  2  2 -5  3  5  7  8  9 -5 




#  Matrix derived from genetic algorithm-based optimization of hydrophobicity scales 
(Zviling et al. 2005) 
   A  C  D  E  F  G  H  I  K  L  M  N  P  Q  R  S  T  V  W  Y  * 
A  9  6 -4  0  7  7  3  8 -1  7  8  1 -2  1 -8  6  7  8  8  3  7 
C  6  9 -2  2  7  8  5  6  1  4  7  4  0  3 -5  8  8  6  7  6  8 
D -4 -2  9  5 -3 -2  2 -4  6 -6 -3  3  7  4  5 -2 -2 -4 -3  1 -2 
E  0  2  5  9  1  2  6  0  7 -2  1  7  6  8  1  2  2  0  1  5  2 
F  7  7 -3  1  9  8  4  7  0  5  8  2 -1  2 -6  7  8  7  8  5  8 
G  7  8 -2  2  8  9  4  6  1  5  7  3  0  3 -6  8  8  7  8  5  8 
H  3  5  2  6  4  4  9  2  5  1  3  7  4  7 -2  5  4  2  3  8  4 
I  8  6 -4  0  7  6  2  9 -2  7  7  1 -3  1 -8  6  6  8  7  3  7 
K -1  1  6  7  0  1  5 -2  9 -3  0  6  7  6  2  1  1 -1  0  4  0 
L  7  4 -6 -2  5  5  1  7 -3  9  6 -1 -4 -1 -9  4  5  7  6  1  5 
M  8  7 -3  1  8  7  3  7  0  6  9  2 -2  2 -7  7  7  8  8  4  8 
N  1  4  3  7  2  3  7  1  6 -1  2  9  5  8  0  3  3  1  2  6  3 
P -2  0  7  6 -1  0  4 -3  7 -4 -2  5  9  5  3  0  0 -2 -1  3 -1 
Q  1  3  4  8  2  3  7  1  6 -1  2  8  5  9  0  3  3  1  2  6  3 
R -8 -5  5  1 -6 -6 -2 -8  2 -9 -7  0  3  0  9 -5 -6 -8 -7 -2 -6 
S  6  8 -2  2  7  8  5  6  1  4  7  3  0  3 -5  9  8  6  7  6  8 
T  7  8 -2  2  8  8  4  6  1  5  7  3  0  3 -6  8  9  6  7  5  8 
V  8  6 -4  0  7  7  2  8 -1  7  8  1 -2  1 -8  6  6  9  7  3  7 
W  8  7 -3  1  8  8  3  7  0  6  8  2 -1  2 -7  7  7  7  9  4  8 
Y  3  6  1  5  5  5  8  3  4  1  4  6  3  6 -2  6  5  3  4  9  5 





Appendix E. CoMTraP Perl program code. 



















# CT: Matthews correlation index (Matthews 1975) that attempts to 
capture both over- and underprediction of residues in transmembrane 
helices by one single score. 
# Q_htm_obs: Percentage of correctly predicted transmembrane helices, 
estimating the likelihood that an actual membrane helix is correctly 
predicted. 
# Q_htm_prd: Percentage of the TM prediction in which the transmembrane 
helices are corrected predicted. 
 
 






























































































$transmembrane_prediction{$protein_name[0]}{$prediction_method[0]} ="  
4- 24  35- 51  64- 80  91-107 129-145 150-169 207-223 230-247 264-280 
282-296 324-341 347-362 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[1]} ="  
6- 14  44- 48  68- 93 131-145 156-169 203-217 223-250 269-283 289-311 
357-371 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[2]} ="  
1- 20  40- 56  74- 94 154-175 195-218 235-256 264-282 291-309 320-343 
356-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[3]} ="  
6- 24  35- 54  67- 85  90-109 128-146 155-172 195-218 227-251 264-282 
291-309 328-347 356-373 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[4]} ="  
7- 24  40- 58  67- 83  90-109 128-147 155-172 195-218 229-253 265-282 
291-313 322-345 352-369 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[5]} ="  
1- 28  34- 60  66- 84  88-115 121-150 154-173 200-228 235-260 262-285 
291-317 325-350 355-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[6]} =" 
67- 84  90-109 128-147 155-172 200-218 239-256 262-282 291-309 322-342 
"; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[7]} ="  
2- 24  37- 59  66- 85  90-112 125-147 157-174 195-217 232-254 267-286 
291-313 320-342 352-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[8]} ="  
4- 26  32- 54  69- 91 127-149 153-175 205-227 235-256 263-285 291-313 
346-368 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[9]} ="  
1- 25  61- 83  83- 99 127-151 155-172 200-220 225-255 264-282 286-310 
357-375 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[10]}="  
2- 24  37- 59  66- 85  90-112 125-147 157-174 195-217 232-254 267-286 
291-313 320-342 352-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[11]}="  
1- 18  36- 54  66- 83 128-147 153-172 200-224 228-253 262-282 294-313 
359-375 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[12]}="  
1- 21  39- 59  66- 86 127-147 155-175 200-220 235-255 263-283 293-313 
329-349 355-375 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[13]}="  
1- 22  64- 84  87-107 127-149 152-174 199-224 226-252 265-288 291-314 
354-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[14]}="  
2- 16  39- 58  66-109 131-145 147-169 195-225 227-256 269-288 290-317 
319-341 343-374 "; 
$transmembrane_prediction{$protein_name[0]}{$prediction_method[15]}="  
2- 22  37- 59  68- 98 128-150 153-175 201-226 229-253 266-289 292-314 




3- 21  39- 57  65- 83  91-109 127-145 155-173 205-223 233-251 265-283 
292-310 330-348 355-373 "; 
 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[0]} =" 
13- 32  36- 67  79-108 128-161 198-222 230-254 299-321 390-412 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[1]} =" 
15- 32  51- 71  84-104 151-167 206-216 233-255 324-325 339-352 359-371 
384-389 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[2]} =" 
16- 36  49- 70  87-107 151-169 200-218 234-256 339-367 380-398 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[3]} =" 
17- 36  53- 72  85-104 151-169 200-218 233-251 301-325 342-366 379-396 
"; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[4]} =" 
16- 33  56- 73  85-104 151-168 197-218 231-251 341-365 379-395 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[5]} =" 
11- 30  46- 72  79-108 150-168 194-218 224-253 260-274 313-328 335-349 
383-414 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[6]} =" 
16- 34  56- 73  85-104 151-169 197-217 231-251 346-367 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[7]} =" 
13- 35  50- 72  85-107 146-168 197-219 234-256 342-364 379-401 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[8]} =" 
11- 33  48- 70  82-104 150-172 199-221 229-251 314-336 346-368 377-399 
"; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[9]} =" 
13- 36  46- 70  82-115 145-168 201-219 230-259 315-332 337-351 358-373 
379-394 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[10]}=" 
13- 35  50- 72  85-107 146-168 197-219 234-256 342-364 379-401 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[11]}=" 
16- 35  56- 76  85-104 151-169 200-222 231-251 339-367 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[12]}=" 
15- 35  56- 76  85-105 150-170 198-218 231-251 292-312 316-336 347-367 
376-396 "; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[13]}=" 
11- 37  51- 76  80-110 146-170 197-223 228-258 333-355 358-375 378-399 
"; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[14]}=" 
16- 36  53- 73  85-113 142-165 200-218 231-256 309-334 336-370 372-393 
"; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[15]}=" 
15- 37  52- 74  84-106 148-170 199-221 231-254 313-341 344-371 375-397 
"; 
$transmembrane_prediction{$protein_name[1]}{$prediction_method[16]}=" 




16- 35  41- 63  89-124 167-185 191-215 238-265 280-299 340-367 377-394 
400-425 448-472 485-503 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[1]} =" 
15- 19  43- 60  92-124 165-184 198-216 247-264 297-309 322-329 337-358 




13- 31  42- 61  89-109 166-187 198-216 243-265 297-314 339-360 378-396 
405-427 447-467 483-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[3]} =" 
12- 29  42- 61  92-111 165-184 197-216 243-262 293-312 339-358 377-396 
409-428 447-466 481-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[4]} =" 
12- 29  39- 61  68- 85  92-111 166-184 197-216 243-266 291-315 339-360 
378-396 405-429 447-468 488-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[5]} =" 
13- 36  41- 68  90-123 165-187 191-216 238-267 275-308 339-370 376-401 
403-429 445-470 482-510 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[6]} =" 
12- 29  42- 61  92-111 166-184 197-216 243-263 291-309 311-331 337-353 
378-396 410-427 447-468 488-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[7]} ="  
7- 29  39- 61  89-111 165-187 194-216 243-265 293-315 335-357 378-395 
405-427 447-469 484-503 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[8]} ="  
6- 28  41- 63  88-110 112-133 164-186 196-218 243-265 292-314 340-362 
377-399 407-429 453-475 483-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[9]} =" 
11- 26  41- 63  91-115 163-186 195-217 243-266 291-322 334-366 378-396 
406-429 454-470 482-503 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[10]}="  
7- 29  39- 61  89-111 165-187 194-216 243-265 293-315 335-357 378-395 
405-427 447-469 484-503 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[11]}="  
8- 29  43- 63  92-111 166-184 194-216 242-266 291-315 339-358 378-396 
405-428 450-469 483-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[12]}="  
9- 29  41- 61  91-111 164-184 194-214 247-267 291-311 335-355 377-397 
409-429 449-469 485-505 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[13]}=" 
39- 64  88-113 162-188 195-220 242-267 293-326 332-364 377-398 404-430 
449-472 483-507 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[14]}=" 
12- 29  39- 66  87-120 166-184 197-216 241-263 297-323 325-360 378-396 
405-429 447-468 483-504 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[15]}="  
8- 30  41- 63  92-120 163-185 196-218 244-266 294-316 320-341 344-364 
376-398 406-428 450-472 483-505 "; 
$transmembrane_prediction{$protein_name[2]}{$prediction_method[16]}=" 
13- 31  42- 60  96-114 167-185 196-214 245-263 288-306 341-359 380-398 
408-426 450-468 482-500 "; 
 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[0]} =" 
12- 27  63- 80  98-115 125-141 157-175 184-199 205-220 223-237 255-273 
295-313 330-348 363-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[1]} =" 
15- 28  65- 77  98-114 134-176 134-176 184-199 207-220 226-235 258-270 
285-312 330-348 366-373 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[2]} =" 
14- 29  60- 77  94-115 128-146 155-175 181-202 205-220 224-240 258-275 




12- 31  58- 77  96-115 134-158 179-202 213-237 258-276 287-311 328-352 
363-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[4]} =" 
12- 29  59- 77  94-115 126-145 154-174 181-202 209-233 258-276 287-311 
328-351 363-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[5]} =" 
15- 25  58- 84 105-115 130-139 150-174 181-199 206-221 263-273 284-298 
301-311 324-348 355-382 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[6]} =" 
12- 29  59- 77  98-115 134-152 154-174 179-197 216-237 258-276 292-312 
328-346 363-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[7]} ="  
7- 29  60- 77  94-116 126-145 152-174 179-201 206-237 257-279 291-313 
328-350 357-379 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[8]} =" 
11- 32  58- 79  93-115 126-148 153-175 181-202 212-234 253-274 291-313 
327-349 357-379 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[9]} =" 
11- 34  58- 79  92-115 125-146 151-174 179-200 205-221 223-238 254-275 
284-315 326-352 360-381 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[10]}="  
7- 29  60- 77  94-116 126-145 152-174 179-201 206-237 257-279 291-313 
328-350 357-379 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[11]}=" 
12- 32  59- 77  94-115 125-152 155-176 179-199 205-233 259-276 283-305 
328-348 363-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[12]}=" 
12- 32  58- 78  95-115 126-146 154-174 179-199 220-240 254-274 282-302 
328-348 360-380 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[13]}="  
8- 34  57- 81  92-118 126-148 151-176 179-201 205-239 252-275 278-307 
324-352 357-379 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[14]}=" 
12- 33  59- 77  91-115 125-153 155-169 171-203 205-239 257-277 279-312 
328-351 363-377 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[15]}=" 
10- 32  59- 81  95-117 128-152 154-177 180-202 205-236 256-278 286-312 
328-351 359-381 "; 
$transmembrane_prediction{$protein_name[3]}{$prediction_method[16]}=" 
13- 31  61- 79  96-114 128-145 155-173 180-198 258-276 290-308 330-348 
362-380 "; 
 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[0]} ="  
8- 31  46- 67  74- 91 106-129 141-161 170-188 223-244 260-279 290-309 
314-334 350-370 382-400 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[1]} =" 
10- 30  47- 64  75-116 153-162 170-187 224-232 274-282 294-303 315-332 
348-367 381-400 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[2]} =" 
10- 27  47- 64  75- 95 103-124 145-162 168-186 222-239 260-278 291-309 
315-331 347-365 381-402 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[3]} ="  
9- 26  47- 66  75- 98 103-122 145-164 169-187 222-239 260-283 292-310 




10- 34  46- 66  75- 96 103-125 145-162 169-187 222-239 260-283 291-313 
321-337 349-370 385-409 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[5]} ="  
6- 36  42- 68  74- 92  94-112 114-134 140-163 168-187 221-250 257-284 
289-307 312-339 345-375 380-399 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[6]} ="  
9- 27  47- 66  76- 95 103-125 145-164 167-187 222-239 260-283 291-309 
349-369 383-400 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[7]} =" 
13- 35  45- 67  76- 98 103-125 145-164 168-187 222-239 261-283 304-326 
346-368 380-402 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[8]} =" 
11- 33  44- 66  75- 97 106-128 144-166 174-196 215-237 260-282 288-310 
313-335 346-368 379-401 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[9]} =" 
10- 33  44- 66  75- 99 103-127 145-165 170-189 222-237 270-285 292-316 
322-337 345-371 378-403 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[10]}=" 
13- 35  45- 67  76- 98 103-125 145-164 168-187 222-239 261-283 304-326 
346-368 380-402 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[11]}="  
9- 27  44- 67  75- 99 103-129 145-164 168-187 222-239 260-283 286-318 
315-341 349-368 380-397 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[12]}="  
7- 27  45- 65  78- 98 102-122 167-187 219-239 263-283 291-311 315-335 
349-369 382-402 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[13]}="  
7- 31  43- 68  74- 98 100-125 145-165 167-191 263-286 288-310 313-337 
345-371 378-405 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[14]}="  
8- 34  46- 66  75-101 103-125 145-165 167-192 266-288 291-310 349-366 
368-406 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[15]}="  
8- 34  42- 70  75-100 105-129 141-163 166-188 221-249 254-278 288-310 
312-334 347-374 377-399 "; 
$transmembrane_prediction{$protein_name[4]}{$prediction_method[16]}=" 
11- 29  46- 64  77- 95 104-122 145-163 168-186 221-239 262-280 289-307 
315-333 355-373 384-402 "; 
 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[0]} =" 
29- 51  63- 83  90-110 121-140 159-178 189-207 256-279 290-309 322-341 
346-368 386-407 413-432 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[1]} =" 
29- 42  69- 77  95-132 170-181 189-206 253-271 324-338 349-371 388-405 
416-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[2]} =" 
25- 43  64- 82  93-111 119-137 167-182 188-206 253-272 292-310 321-339 
348-369 389-403 416-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[3]} =" 
29- 51  64- 82  93-112 119-141 154-178 187-206 253-272 293-312 321-340 
353-372 385-404 417-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[4]} =" 
27- 43  64- 85  93-112 119-137 166-182 189-207 253-272 292-311 321-340 




22- 55  62- 87  93-112 118-133 137-147 151-181 186-206 252-281 288-315 
321-340 347-373 379-407 414-433 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[6]} =" 
27- 43  64- 85  93-112 114-132 165-182 187-207 253-272 321-340 350-369 
383-403 416-435 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[7]} =" 
27- 44  64- 86  93-115 119-141 154-176 186-205 253-272 292-311 318-340 
350-372 385-407 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[8]} =" 
26- 43 102-124 160-181 187-208 251-273 290-312 320-342 350-372 384-406 
414-435 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[9]} =" 
21- 43  64- 83  94-115 119-137 158-182 187-207 252-267 291-311 321-341 
348-375 381-406 412-434 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[10]}=" 
27- 44  64- 86  93-115 119-141 154-176 186-205 253-272 292-311 318-340 
350-372 385-407 417-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[11]}=" 
25- 43  63- 85  93-112 114-132 187-207 253-272 321-340 350-369 383-407 
414-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[12]}=" 
25- 45  66- 86  94-114 163-183 187-207 252-272 292-312 321-341 350-370 
384-404 415-435 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[13]}=" 
91-113 115-138 163-184 187-210 251-274 319-341 345-372 384-409 412-438 
"; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[14]}=" 
29- 45  64- 78  93-110 112-141 162-188 190-207 252-272 324-341 344-369 
383-405 407-436 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[15]}=" 
35- 57  62- 84  91-113 119-141 159-181 187-209 260-282 286-308 320-342 
346-368 387-409 413-435 "; 
$transmembrane_prediction{$protein_name[5]}{$prediction_method[16]}=" 
25- 43  66- 84  92-110 119-137 158-176 187-205 253-271 292-310 322-340 
349-367 386-404 412-430 "; 
 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[0]} =" 
63- 90 116-138 145-167 169-179 206-229 233-257 299-323 340-360 389-399 
402-423 436-459 470-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[1]} =" 
64- 87 121-129 148-161 169-181 215-230 235-257 302-323 340-358 389-419 
444-456 472-487 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[2]} =" 
65- 88 140-161 211-229 237-255 305-323 337-358 379-397 403-424 437-457 
470-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[3]} =" 
67- 91 118-137 146-165 170-189 210-229 234-257 299-323 340-358 379-398 
403-422 435-458 471-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[4]} =" 
63- 79 146-165 206-229 237-257 304-323 340-359 402-422 436-459 470-490 
"; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[5]} =" 
60- 91 112-139 144-183 186-196 202-231 236-255 302-331 338-365 373-394 




63- 79 118-138 146-165 210-229 237-255 304-323 340-359 403-422 436-456 
471-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[7]} =" 
69- 91 116-138 145-167 206-228 233-255 301-323 340-362 402-424 436-458 
"; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[8]} =" 
63- 85 138-160 163-185 207-229 238-260 304-326 338-360 402-423 470-491 
"; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[9]} =" 
56- 92 117-137 139-164 205-229 233-257 298-325 340-362 400-424 431-463 
469-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[10]}=" 
69- 91 116-138 145-167 206-228 233-255 301-323 340-362 402-424 436-458 
468-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[11]}=" 
63- 88 115-137 146-165 170-195 210-229 239-257 298-319 340-357 402-422 
436-459 470-489 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[12]}=" 
62- 82 118-138 145-165 209-229 237-257 297-317 340-360 379-399 402-422 
440-460 470-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[13]}=" 
58- 86 143-164 167-188 208-234 237-259 304-324 335-362 396-423 438-461 
469-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[14]}=" 
63- 88 116-138 141-175 210-231 233-257 302-323 340-359 382-422 436-459 
470-490 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[15]}=" 
63- 87 115-137 142-162 165-184 210-232 235-256 302-324 340-362 382-402 
405-424 440-462 469-491 "; 
$transmembrane_prediction{$protein_name[6]}{$prediction_method[16]}=" 
66- 84 118-136 145-163 172-190 211-229 235-253 304-322 342-360 378-396 




























for ($p=$total_count;$p>0;$p--) { 
$pattern=dec2bin($p,$number_of_prediction); 
$max_cutoff=digit_sum($pattern); 






























for ($n=1;$n<($number_of_prediction+1);$n++) { 


















for ($i=0;$i<length($protein_sequence[$m]);$i++) { 











for ($i=0;$i<length($protein_sequence[$m]);$i++) { 
push (@positive_prediction,"0"); 
} 
for ($i=0;$i<length($protein_sequence[$m]);$i++) { 





} until (($the_observed[$i]==0) || ($consensus_prediction[$i]==0)); 
if (($the_observed[$i]==0) && ($consensus_prediction[$i]==1)) { 
do { 
$i++; 
} until ($consensus_prediction[$i+1]==0); 
} 
if (($the_observed[$i]==1) && ($consensus_prediction[$i]==0)) { 
do { 
$i++; 





if (($consensus_prediction[$i]==0) && $the_observed[$i]==0) { 
$true_negative++; 
} 
if (($consensus_prediction[$i]==1) && $positive_prediction[$i]==0) { 
$false_positive++; 
} 













if ($predicted_transmembrane_number>0) { 
$sum_of_Q_htm_prd+=$true_positive/$predicted_transmembrane_number*100; 




















if ($CT_Ranking_Pattern>=$top_CT_pattern_cutoff[0]) { 
shift @top_CT_pattern_cutoff; 
push (@top_CT_pattern_cutoff,$CT_Ranking_Pattern); 




if ($Q_htm_obs_Ranking_Pattern>=$top_Q_htm_obs_pattern_cutoff[0]) { 
shift @top_Q_htm_obs_pattern_cutoff; 
push (@top_Q_htm_obs_pattern_cutoff,$Q_htm_obs_Ranking_Pattern); 




if ($Q_htm_prd_Ranking_Pattern>=$top_Q_htm_prd_pattern_cutoff[0]) { 
shift @top_Q_htm_prd_pattern_cutoff; 
push (@top_Q_htm_prd_pattern_cutoff,$Q_htm_prd_Ranking_Pattern); 







# Transmembrane predictions of rVGLUT1 by CT 
 
@sorted_data=sort {$b cmp $a} @top_CT_pattern_cutoff; 
@top_CT_pattern_cutoff=@sorted_data; 
open (Output_File,">CT_Ranking_Data".time().".txt"); 
for ($t=0;$t<$pick_number;$t++) { 





print "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) MINNOU(5) 
PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 









print Output_File "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) 
MINNOU(5) PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 
TopPred(12) TSEG(13) waveTM(14) SVMtop (15) ZPRED(16)","\n\n"; 
print Output_File "Previous 
prediction\n",$transmembrane_prediction{$protein_name[6]}{$prediction_m
ethod[0]},"\n\n"; 














for ($n=1;$n<($number_of_prediction+1);$n++) { 


















for ($i=0;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_score[$i]>=$cutoff) { 
push (@consensus_prediction,"1"); 






for ($i=1;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_prediction[$i]>$consensus_prediction[$i-1]) { 
$start_residue=$i; 
} 
if ($consensus_prediction[$i]<$consensus_prediction[$i-1]) { 
$transmembrane_length=$i-$start_residue; 
if (($transmembrane_length<9) || ($transmembrane_length>45)) { 
goto next_segment; 
} else { 
 
 119












print Output_File $consensus_transmembrane_prediction_segment[$i]; 
} 
print "\n\n"; 




# Transmembrane predictions of rVGLUT1 by Q_htm_obs 
 
@sorted_data=sort {$b cmp $a} @top_Q_htm_obs_pattern_cutoff; 
@top_Q_htm_obs_pattern_cutoff=@sorted_data; 
open (Output_File,">Q_htm_obs_Ranking_Data".time().".txt"); 
for ($t=0;$t<$pick_number;$t++) { 





print "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) MINNOU(5) 
PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 







print Output_File "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) 
MINNOU(5) PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 
TopPred(12) TSEG(13) waveTM(14) SVMtop (15) ZPRED(16)","\n\n"; 
print Output_File "Previous 
prediction\n",$transmembrane_prediction{$protein_name[6]}{$prediction_m
ethod[0]},"\n\n"; 
















for ($n=1;$n<($number_of_prediction+1);$n++) { 


















for ($i=0;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_score[$i]>=$cutoff) { 
push (@consensus_prediction,"1"); 






for ($i=1;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_prediction[$i]>$consensus_prediction[$i-1]) { 
$start_residue=$i; 
} 
if ($consensus_prediction[$i]<$consensus_prediction[$i-1]) { 
$transmembrane_length=$i-$start_residue; 
if (($transmembrane_length<9) || ($transmembrane_length>45)) { 
goto next_segment; 
} else { 












print Output_File $consensus_transmembrane_prediction_segment[$i]; 
} 
print "\n\n"; 






# Transmembrane predictions of rVGLUT1 by Q_htm_prd 
 
@sorted_data=sort {$b cmp $a} @top_Q_htm_prd_pattern_cutoff; 
@top_Q_htm_prd_pattern_cutoff=@sorted_data; 
open (Output_File,">Q_htm_prd_Ranking_Data".time().".txt"); 
for ($t=0;$t<$pick_number;$t++) { 





print "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) MINNOU(5) 
PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 







print Output_File "DAS_TMfilter(1) HMMTM(2) HMMTOP(3) MEMSAT(4) 
MINNOU(5) PRED_TMR2(6) SMART(7) SOSUI(8) SPLIT(9) TMHMM(10) TMpred(11) 
TopPred(12) TSEG(13) waveTM(14) SVMtop (15) ZPRED(16)","\n\n"; 
print Output_File "Previous 
prediction\n",$transmembrane_prediction{$protein_name[6]}{$prediction_m
ethod[0]},"\n\n"; 














for ($n=1;$n<($number_of_prediction+1);$n++) { 




















for ($i=0;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_score[$i]>=$cutoff) { 
push (@consensus_prediction,"1"); 






for ($i=1;$i<length($protein_sequence[6]);$i++) { 
if ($consensus_prediction[$i]>$consensus_prediction[$i-1]) { 
$start_residue=$i; 
} 
if ($consensus_prediction[$i]<$consensus_prediction[$i-1]) { 
$transmembrane_length=$i-$start_residue; 
if (($transmembrane_length<9) || ($transmembrane_length>45)) { 
goto next_segment; 
} else { 












print Output_File $consensus_transmembrane_prediction_segment[$i]; 
} 
print "\n\n"; 







### Functions ######################################## 
 
















} until ($quotient<1); 
if ($digit_number>length($binary_string)) { 
$output=substr($fill,0,$digit_number-
length($binary_string)).$binary_string; 






sub digit_sum() { 
my ($input)=@_; 
my $output=0; 















Appendix F. Representive MASCOT output of MS analysis of His6-tagged rVGLUT1. 
rVGLUT1 HisTag [Rattus norvegicus] 
 
Nominal mass (Mr): 64721; Calculated pI value: 6.52 
Variable modifications: GlyGly (K),Oxidation (M) 
Cleavage by Trypsin/V8E: cuts C-term side of EKRZ unless next residue is P 
Sequence Coverage: 57% 
 
Matched peptides shown in Bold Red 
 
     1 MEFRQEEFRK LAGRALGRLH RLLEKRQEGA ETLELSADGR PVTTHTRDPP  
    51 VVDCTCFGLP RRYIIAIMSG LGFCISFGIR CNLGVAIVSM VNNSTTHRGG  
   101 HVVVQKAQFN WDPETVGLIH GSFFWGYIVT QIPGGFICQK FAANRVFGFA  
   151 IVATSTLNML IPSAARVHYG CVIFVRILQG LVEGVTYPAC HGIWSKWAPP  
   201 LERSRLATTA FCGSYAGAVV AMPLAGVLVQ YSGWSSVFYV YGSFGIFWYL  
   251 FWLLVSYESP ALHPSISEEE RKYIEDAIGE SAKLMNPVTK FNTPWRRFFT  
   301 SMPVYAIIVA NFCRSWTFYL LLISQPAYFE EVFGFEISKV GLVSALPHLV  
   351 MTIIVPIGGQ IADFLRSRHI MSTTNVRKLM NCGGFGMEAT LLLVVGYSHS  
   401 KGVAISFLVL AVGFSGFAIS GFNVNHLDIA PRYASILMGI SNGVGTLSGM  
   451 VCPIIVGAMT KHKTREEWQY VFLIASLVHY GGVIFYGVFA SGEKQPWAEP  
   501 EEMSEEKCGF VGHDQLAGSD ESEMEDEVEP PGAPPAPPPS YGATHSTVQP  
   551 PRPPPPVRDY AAASFLEQKL ISEEDLNSAV DHHHHHH 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
     5 - 10      836.76   835.75   835.92    -0.16     3  QEEFRK 
     8 - 25     2249.49  2248.48  2248.71    -0.23     6  FRKLAGRALGRLHRLLEK GlyGly (K) 
    19 - 28     1436.40  1435.39  1435.65    -0.26     4  LHRLLEKRQE GlyGly (K) 
    19 - 31     1693.68  1692.67  1692.90    -0.23     5  LHRLLEKRQEGAE GlyGly (K) 
    25 - 47     2553.17  2552.16  2552.79    -0.63     5  KRQEGAETLELSADGRPVTTHTR 
    26 - 47     2425.21  2424.20  2424.61    -0.41     4  RQEGAETLELSADGRPVTTHTR 
    27 - 47     2268.95  2267.94  2268.43    -0.48     3  QEGAETLELSADGRPVTTHTR 
    29 - 62     3669.24  3668.23  3668.12     0.11     4  GAETLELSADGRPVTTHTRDPPVVDCTCFGLPRR 
    35 - 47     1411.44  1410.43  1410.55    -0.12     0  LSADGRPVTTHTR 
   115 - 140    2870.41  2869.40  2869.38     0.03     0  TVGLIHGSFFWGYIVTQIPGGFICQK 
   146 - 166    2180.70  2179.70  2179.61     0.09     0  VFGFAIVATSTLNMLIPSAAR 
   177 - 202    2866.36  2865.35  2865.34     0.01     2  ILQGLVEGVTYPACHGIWSKWAPPLE 
   184 - 205    2627.07  2626.06  2625.99     0.07     3  GVTYPACHGIWSKWAPPLERSR GlyGly (K) 
   197 - 203     868.91   867.90   868.00    -0.10     1  WAPPLER 
   270 - 280    1323.31  1322.30  1322.44    -0.14     4  ERKYIEDAIGE 
   270 - 280    1437.34  1436.34  1436.54    -0.21     4  ERKYIEDAIGE GlyGly (K) 
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   270 - 290    2409.55  2408.54  2408.76    -0.21     6  ERKYIEDAIGESAKLMNPVTK Oxidation (M) 
   270 - 290    2507.92  2506.91  2506.86     0.05     6  ERKYIEDAIGESAKLMNPVTK GlyGly (K) 
   271 - 280    1308.17  1307.16  1307.43    -0.26     3  RKYIEDAIGE GlyGly (K) 
   272 - 283    1324.47  1323.46  1323.47    -0.00     3  KYIEDAIGESAK 
   272 - 290    2336.92  2335.92  2335.66     0.26     4  KYIEDAIGESAKLMNPVTK 2 GlyGly (K) 
   273 - 290    2208.04  2207.03  2207.49    -0.46     3  YIEDAIGESAKLMNPVTK 2 GlyGly (K) 
   281 - 290    1105.61  1104.60  1104.33     0.27     1  SAKLMNPVTK Oxidation (M) 
   284 - 296    1620.82  1619.81  1619.91    -0.09     1  LMNPVTKFNTPWR Oxidation (M) 
   291 - 296     820.93   819.92   819.92     0.00     0  FNTPWR 
   291 - 297     977.07   976.07   976.11    -0.04     1  FNTPWRR 
   315 - 336    2688.10  2687.09  2687.04     0.05     2  SWTFYLLLISQPAYFEEVFGFE 
   367 - 377    1302.39  1301.39  1301.49    -0.10     1  SRHIMSTTNVR 
   379 - 388    1059.49  1058.49  1058.25     0.23     0  LMNCGGFGME 
   379 - 401    2461.35  2460.34  2459.88     0.46     1  LMNCGGFGMEATLLLVVGYSHSK 2 Oxidation (M) 
   433 - 461    2901.64  2900.63  2900.52     0.11     0  YASILMGISNGVGTLSGMVCPIIVGAMTK Oxidation (M) 
   433 - 463    3296.91  3295.91  3295.95    -0.04     1  YASILMGISNGVGTLSGMVCPIIVGAMTKHK GlyGly (K); 2 Oxidation (M) 
   433 - 465    3636.06  3635.06  3635.34    -0.28     2  YASILMGISNGVGTLSGMVCPIIVGAMTKHKTR 2 GlyGly (K) 
   467 - 493    3053.95  3052.94  3052.48     0.46     1  EWQYVFLIASLVHYGGVIFYGVFASGE 
   494 - 507    1962.87  1961.86  1962.08    -0.22     5  KQPWAEPEEMSEEK 2 GlyGly (K); Oxidation (M) 
   494 - 521    3151.22  3150.21  3150.36    -0.15     6  KQPWAEPEEMSEEKCGFVGHDQLAGSDE Oxidation (M) 
   503 - 523    2370.02  2369.01  2369.48    -0.46     4  MSEEKCGFVGHDQLAGSDESE GlyGly (K) 
   503 - 525    2630.31  2629.30  2629.78    -0.48     5  MSEEKCGFVGHDQLAGSDESEME GlyGly (K) 
   559 - 573    1799.94  1798.94  1798.97    -0.03     2  DYAAASFLEQKLISE GlyGly (K) 
   570 - 587    2128.23  2127.22  2127.22     0.00     2  LISEEDLNSAVDHHHHHH 
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Appendix G Multiple sequence alignments with selected amino acid substitution matrices 
(Appendix D).  Experimental and CoMTrap-predicted transmembrane regions 




MSA with the amino acid substitution matrix based on BLOSUM62 (Henikoff and Henikoff 1992).  TmA 130. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -------------------------------------------------------MYYLKNTNFWMFGLFFFFYFFIMGAYFPFFPIWLHDINHISKSDT  
GlpT_1PW4_A  ------------------------------------GSIFKPAPHKARLPAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFALAMPYLVEQGFSRGDL  
EmrD_2GFP_A  ---------------------------------------------------------------LLLMLVLLVAVGQMAQTIYIPAIADMARDLNVREGAV  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  GIIFAAISLFSLLFQPLFGLLSDKLGLRKYLLWIITG--------------MLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFIEK  
GlpT_1PW4_A  GFALSGISIAYGFSKFIMGSVSDRSNPRVFLPA--------------GLILAAAVMLFMGFVPWATSSIAVMFVLLFLCGWFQGMGWPPCGRTMVHWWSQ  
EmrD_2GFP_A  QSVMGAYLLTYGVSQLFYGPISDR----VGRRP--------------VILVGMSIFMLATLVAVTTSSLTVLIAASAMQGMGTGVGGVMARTLPRDLYER  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPP  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  VSRRSNFEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTDAPSSATVANAVGANHSAFSLKLALELFRQPKLWFLSLYVIG  
GlpT_1PW4_A  KERGGIVSVWNCAHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYNEKAEQELTAKQIFMQYVLP  
EmrD_2GFP_A  TQLRHANSLLNMGILVSPLLAPLIGGLLDTMWNWRACYLFLLVLCAGVTFSMARWMPETRPVDAPR-----------------------TRLLTSYKTLF  
rVGLUT1      LERSRLATTAFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPWRRFFT  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  VSCTYDVFDQQFANFFTSFFATGEQGTRVFGYVTTMGELLN-------------------ASIMFFAPLIINRIGGKNALLLAGTIMSVRIIGSSFATSA  
GlpT_1PW4_A  NKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKS--------SWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATGVFFMTLVTIATIVYWMNP  
EmrD_2GFP_A  GNSGFNCYLLMLIGGLAGIAAFEACSGVLMGAVLGLSSMT--------VSILFILPIPAAFFGAWFAGRPNKRFSTLMWQSVICCLLAGLLMWIPDWFGV  
rVGLUT1      SMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVVGYSHS  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  LEVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIGFQGAYLVLGLVALGFTLISVFTLSGPGPLSLLRRQ  
GlpT_1PW4_A  AGNPTVDMICMIVIGFLIYGPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFGWDGGFMVMIGGSILAVILLIVVMIGEKRRHE  
EmrD_2GFP_A  MN--VWTLLVPAALFFFGAGMLFPLATSGAMEPFPFLAGTAGALVGGLQNIGSGVLASLSAMLPQTGQGSLGLLMTLMGLLIVLCWLPL-----------  
rVGLUT1      KGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQPWAEP  
 
                     510       520       530       540       550       560      
             ....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  VNEVA-------------------------------------------------------  
GlpT_1PW4_A  QLLQELVPR---------------------------------------------------  
EmrD_2GFP_A  ------------------------------------------------------------  
rVGLUT1      EEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
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MSA with the amino acid substitution matrix based on Dayhoff Matrix (Dayhoff  1978; Zintzaras 1999).  TmA 157. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -----------------------------------------------------------------------MYYLKNTNFWMFGLFFFFYFFIMGAYFPF  
GlpT_1PW4_A  ----------------------------------------------------GSIFKPAPHKARLPAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFA  
EmrD_2GFP_A  -------------------------------------------------------------------------------LLLMLVLLVAVGQMAQTIYIP  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  FPIWLHDINHISKSDTGIIFAAISLFSLLFQPLFGLLSDKLGLRKYLLWIITGMLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFI  
GlpT_1PW4_A  LAMPYLVEQGFSRGDLGFALSGISIAYGFSKFIMGSVSDRSNPRVFLPAGLILAAAVMLFMGFVPWATSSIAVMFVLLFLCGWFQGMGWPPCGRTMVHWW  
EmrD_2GFP_A  AIADMARDLNVREGAVQSVMGAYLLTYGVSQLFYGPISDRVGR----RPVILVGMSIFMLATLVAVTTSSLTVLIAASAMQGMGTGVGGVMARTLPRDLY  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAAN--RVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWA  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  EKVSRRSNFEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTDAP--------------SSATVANAVGANHSAFSLKLALE  
GlpT_1PW4_A  SQKERGGIVSVWNCAHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYNEKAEQELTAKQIFMQYV  
EmrD_2GFP_A  ERTQLRHANSLLNMGILVSPLLAPLIGGLLDTMWNWRACYLFLLVLCAGVTFSMARWMP-----------------------ETRPVDAPRTRLLTSYKT  
rVGLUT1      PPLERSRLATTAFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPWRRF  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  LFRQPKLWFLSLYVIGVSCTYDVFDQQFANFFTSFFATGEQG-----TRVFGYVTTMGELLNASIMFFAPLIINRIGGKNALLLAGTIMSVRIIGSSFAT  
GlpT_1PW4_A  LPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKS--------SWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATGVFFMTLVTIATIVYWM  
EmrD_2GFP_A  LFGNSGFNCYLLMLIGGLAGIAAFEACSGVLMGAVLGLSSMT--------VSILFILPIPAAFFGAWFAGRPNKRFSTLMWQSVICCLLAGLLMWIPDWF  
rVGLUT1      FTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVVGYS  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  SALEVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIGFQGAYLVLGLVALGFTLISVFTLSGPGPLSLLR  
GlpT_1PW4_A  NPAGNPTVDMICMIVIGFLIYGPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFGWDGGFMVMIGGSILAVILLIVVMIGEKRR  
EmrD_2GFP_A  GVMN--VWTLLVPAALFFFGAGMLFPLATSGAMEPFPFLAGTAGALVGGLQNIGSGVLASLSAMLPQTGQGSLGLLMTLMGLLIVLCWLPL---------  
rVGLUT1      HSKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQPWA  
 
                     510       520       530       540       550       560      
             ....|....|....|....|....|....|....|....|....|....|....|....|.. 
LacY_1PV7_A  RQVNEVA-------------------------------------------------------  
GlpT_1PW4_A  HEQLLQELVPR---------------------------------------------------  
EmrD_2GFP_A  --------------------------------------------------------------  
rVGLUT1      EPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
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MSA with the amino acid substitution matrix based on PAM 250 (Dayhoff 1978).  TmA 168. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -----------------------------------------------------------------------MYYLKNTNFWMFGLFFFFYFFIMGAYFPF  
GlpT_1PW4_A  ----------------------------------------------------GSIFKPAPHKARLPAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFA  
EmrD_2GFP_A  -------------------------------------------------------------------------------LLLMLVLLVAVGQMAQTIYIP  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  FPIWLHDINHISKSDTGIIFAAISLFSLLFQPLFGLLSDKLGLRKYLLWIITGMLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFI  
GlpT_1PW4_A  LAMPYLVEQGFSRGDLGFALSGISIAYGFSKFIMGSVSDRSNPRVFLPAGLILAAAVMLFMGFVPWATSSIAVMFVLLFLCGWFQGMGWPPCGRTMVHWW  
EmrD_2GFP_A  AIADMARDLNVREGAVQSVMGAYLLTYGVSQLFYGPISDRVGR----RPVILVGMSIFMLATLVAVTTSSLTVLIAASAMQGMGTGVGGVMARTLPRDLY  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAAN--RVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWA  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  EKVSRRSNFEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTDAP--------------SSATVANAVGANHSAFSLKLALE  
GlpT_1PW4_A  SQKERGGIVSVWNCAHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYNEKAEQELTAKQIFMQYV  
EmrD_2GFP_A  ERTQLRHANSLLNMGILVSPLLAPLIGGLLDTMWNWRACYLFLLVLCAGVTFSMARWMP-----------------------ETRPVDAPRTRLLTSYKT  
rVGLUT1      PPLERSRLATTAFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPWRRF  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  LFRQPKLWFLSLYVIGVSCTYDVFDQQFANFFTSFFATGEQG-------TRVFGYVTTMGELLNASIMFFAPLIINRIGGKNALLLAGTIMSVRIIGSSF  
GlpT_1PW4_A  LPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKS--------SWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATGVFFMTLVTIATIVYWM  
EmrD_2GFP_A  LFGNSGFNCYLLMLIGGLAGIAAFEACSGVLMGAVLGLSSMT--------VSILFILPIPAAFFGAWFAGRPNKRFSTLMWQSVICCLLAGLLMWIPDWF  
rVGLUT1      FTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVVGYS  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  ATSALEVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIGFQGAYLVLGLVALGFTLISVFTLSGPGPLSL  
GlpT_1PW4_A  NPAGNPTVDMICMIVIGFLIYGPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFGWDGGFMVMIGGSILAVILLIVVMIGEKRR  
EmrD_2GFP_A  G------------VMNVWTLLVPAALFFFGAGMLFPLATSGAMEPFPFLAGTAG--ALVGGLQNIGSGVLASLSAMLPQTGQGSLGLLMTLMGLLIVLCW  
rVGLUT1      HSKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQPWA  
 
                     510       520       530       540       550       560      
             ....|....|....|....|....|....|....|....|....|....|....|....|.. 
LacY_1PV7_A  LRRQVNEVA-----------------------------------------------------  
GlpT_1PW4_A  HEQLLQELVPR---------------------------------------------------  
EmrD_2GFP_A  LPL-----------------------------------------------------------  
rVGLUT1      EPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
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MSA with the amino acid substitution matrix based on Kyte-Dolittle hydrophobicity (Kyte 1982).  TmA 146. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -------------------------------MYYLKNTN---FWMFGLFFFFYFFIMGAYFPFFPIWLHDI---------------------NHISKSDT  
GlpT_1PW4_A  ----------------GSIFKPAPHKAR-LPAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFALAMPYL-------------------VEQGFSRGDL  
EmrD_2GFP_A  -----------------------------------------LLLMLVLLVAVGQMAQTIYIPAIADMARDLN------------------VREGAVQSVM  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  GIIFAAISLFSL-------LFQPLFGLLSDKLGLRKYLLW-----IITGMLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFIEKVS  
GlpT_1PW4_A  GFALSGISIAYG-------FSKFIMGSVSDRSN-PRVFLP---AGLILAAAVMLFMGFVPWATSSI----AVMFVLLFLCGWFQGMGWPPCGRTMVHWWS  
EmrD_2GFP_A  GAYL----LTYG-------VSQLFYGPISDRVG-RRPVI-------LVGMSIFMLATLVAVTTSSL----TVLIAASAMQGMGTGVGG-VMARTLPRDLY  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIP-GGFICQKFAANRVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAP  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  RRSN---FEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTDAPSSATVANAVGANHSAFSLK---LALELFRQ-PKLWFLS  
GlpT_1PW4_A  QKERGGIVSVWNC-AHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDD---YNEKAEQELTAKQIFM  
EmrD_2GFP_A  ERTQ---LRHANS-LLNMGILVSPLLAPLIGGLLDTMWNWRACYLFLLVLCAGVTFSMARWMPET---RPVDAPRTRLLTS---YKTLFGNSGFNCYLLM  
rVGLUT1      PLER---SRLATT-AFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPW  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  LYVIG-VSCTYDVFDQQFANFFTSFFATGEQGTR---------VFGYVTTMGELLNASIMFFAPLIINRIGGK----NA----LLLAGTIMSVRIIGSSF  
GlpT_1PW4_A  QYVLPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKSSWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATG----VFFMTLVTIATIVYWMN  
EmrD_2GFP_A  --LIG--GLAGIAAFEACSGVLMGAVLGLSSMTV-----------SILFILPIPAAFFGAWFAGRPNKRFSTL--MWQS----VICCLLAGLLMWIPDWF  
rVGLUT1      RRFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVV  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  ATSALEVVILKT-LHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAM-IFMSVLAGNMYESIGFQGA---YLVLGLVALGFTLISVFTLSGP  
GlpT_1PW4_A  PAGNPTVDMICMIVIGFLIY-GPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFGWDGG--FMVMIGGSILAVILLIVVMIGEK  
EmrD_2GFP_A  GVMNVWTLLVPAALFFFGAG-MLFPLATSGAMEPFP-FLAGTAGALVGGLQNIGSGVLAS--LSAMLP-QTGQGS--LGLLMT---LMGLLIVLCWLP--  
rVGLUT1      GYSHSKGVAISFLVLAVGFSGFAISGFNVNHLDIAP-RYASILMGISNGVGTLSG-MVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGE  
 
                     510       520       530       540       550       560            
             ....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
LacY_1PV7_A  G-PLSLLRRQVNEVA----------------------------------------------------  
GlpT_1PW4_A  RRHEQLLQELVPR------------------------------------------------------  
EmrD_2GFP_A  -----L-------------------------------------------------------------  
rVGLUT1      KQPWAEPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
 
 131
MSA with the amino acid substitution matrix based on Wimley-White hydrophobicity (Wimley 1996). TmA 166. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -----------------------------------------------------MYYLKNTNFWMFGLFFFFYFFIMGAYFP----FFPIWLHDINHISKS  
GlpT_1PW4_A  --------------------------------------GSIFKPAPHKARLPAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFALAMPYLVEQGFSRG  
EmrD_2GFP_A  --------------------------------------------------------------LLLMLVLLVAVGQMAQTIY---IPAIADMARDLNVREG  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  DTGIIFAAISLFSLLF---------QPLFGLLSDKLGLRKYLLWIIT----GMLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFIE  
GlpT_1PW4_A  DLGFALSGISIAYGFS---------KFIMGSVSDRSNPRVFLPAGLI---LAAAVMLFMGFVPWATSSIAVMFVLLFLCGWFQGMGWPPCGRTMVHWWSQ  
EmrD_2GFP_A  AVQSVMGAYLLTYGVS---------QLFYGPISDRVGRRPVILVG-------MSIFMLATLVAVTTSSLTVLIAASAMQGMGTGVGGVMARTLPRDLYER  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPP  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  KVSRRSNFEFGRARMFGCVGWALGASIVGIMFT-INNQFVFWLGSGCALILAVLLFFAKTD----APSSATVANAVG-----------ANHSAFSLKLAL  
GlpT_1PW4_A  KERGGIVSVWNCAHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYNEKAEQELTAKQIFMQ---Y  
EmrD_2GFP_A  TQLRHANSLLNMGILVSPLLAPLIGGLLDTMWN-WRACYLFLLVLCAGVTFSMARWMPET------RPVDAPRTRLL----------TSYKTLFGN---S  
rVGLUT1      LERSRLATTAFCGSYAGAVVAMPLAGVLVQYSG-WSSVFYVYGSFGIFWYLFWLLVSYESP--ALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPWRR  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  ELFRQPKLWFLSLYVIGVSCTYDVFDQQFANFFTSFFATGEQGTRVFGYVTTMGELLNASIMFFAPLIINR-IGGKNALLLAGTIMSVRIIGSSFATSAL  
GlpT_1PW4_A  VLPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKS----SWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATGVFFMTLVTIATIVYWMNPA  
EmrD_2GFP_A  GFN--CYLLMLIG----GLAGIAAFEACSGVL---MGAVLGLS----SMTVSILFILPIPAAFFGAWFAGRPNKRFS-TLMWQSVICCLLAGLLMWIPDW  
rVGLUT1      FFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVVGY  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  EVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIGFQGAYLVLGLVALGFTLISVFTLSGPGPLSLLRRQ-  
GlpT_1PW4_A  GNPTVDMICMIVIGFLIYGPVML-IGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFGWDGGFMVMIGGSILA--VILLIVVMIGEKR-  
EmrD_2GFP_A  FGVMNVWTLLVPAALFFFGAGML-FPLATSG-AMEPFPFLAGTAGALVGGLQN-IGSGVLASLSAMLPQTGQGSLGLLMTLMGL--LIVLCWLPL-----  
rVGLUT1      SHSKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMG-ISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQP  
 
                     510       520       530       540       550       560      
             ....|....|....|....|....|....|....|....|....|....|....|....|.... 
LacY_1PV7_A  ---------------VNEVA--------------------------------------------  
GlpT_1PW4_A  ---------------RHEQLLQ----------ELVPR---------------------------  
EmrD_2GFP_A  ----------------------------------------------------------------  
rVGLUT1      WAEPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
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MSA with the amino acid substitution matrix based on transmembrane-propensity values (Chao 2005).  TmA 164. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  --------------------------------------------------MYYLKNT------NFWMFGLFFFFYFFIMGAYFPFFPIWLHDINHISKSD  
GlpT_1PW4_A  --------------------------GSIFKPAPHKARL----------PAAEIDPTYRRLRWQIFLGIFFGYAAYYLVRKNFALAMPYLVEQG-FSRGD  
EmrD_2GFP_A  ----------------------------------------------------------------LLLMLVLLVAVGQMAQTIYIPAIADMARDLNVREGA  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  TGIIFAAIS------LFSLLFQPLFGLLSDKLG----LRKYLLWIITGMLVMFAPFFIFIFGPLLQYNILVGSIVGGIYLGFCFNAGAPAVEAFIEKVSR  
GlpT_1PW4_A  LGFALSGIS------IAYGFSKFIMGSVSDRSN-----PRVFLP--AGLILAAAVMLFMGFVPWATSSIAVMFVLLFLCGWFQGMGWPPCGRTMVHWWSQ  
EmrD_2GFP_A  VQSVMGAYL------LTYGVSQLFYGPISDRVG-----RRP------VILVGMSIFMLATLVAVTTSSLTVLIAASAMQGMGTGVGG-VMARTLPRDLYE  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPP  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  R---SNFEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTD------APSSATVANAVG--------ANHSAFSLKLALEL-  
GlpT_1PW4_A  KERGGIVSVWNC-AHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYN-EKAEQELTAKQIFMQY-  
EmrD_2GFP_A  R---TQLRHANS-LLNMGILVSPLLAPLIGGLLDTMWNWRACYLFLLVLCAGVTFSMAR------WMPETRPVDAP--------RTRLLTSYKTLFGNS-  
rVGLUT1      LER---SRLATT-AFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPVTKFNTPWR  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  -FRQPK--LWFLSLYVIGVSCTYDVFDQQFANFFTSFFATGEQGTRVFGYVTTMGELLNASIMFFAPLI--INRIGGKN------ALLLAGTIMSVRIIG  
GlpT_1PW4_A  -VLPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKSSWAYFLYEYAGIPGTLLCGWMSDKVFRGNRGATGV------FFMTLVTIATIVYWM  
EmrD_2GFP_A  -GFN------CYLLMLIGGLAGIAAFEACSGVLMGAVLGLSSMTVSILFILPIPAAFFGAWFAGRPNK--RFSTLMWQS------VICCLL--AGLLMWI  
rVGLUT1      RFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEIS-KVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLLLVV  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  SSFATSALEVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIG---FQGAYLVLGLVALGFTLISVFTLSG  
GlpT_1PW4_A  NPAGNPTVDMICMIVIGFLIY-GPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDFFG---WDGGFMVMIGGSILAVILLIVVMIG  
EmrD_2GFP_A  PDWFG-VMNVWTLLVPAALFF-FGAGMLFPLATSGAMEPFP--FLAGTAGALVGGLQNIGSGVLASLSAMLP---QTGQGSLGLLMTLMGLLIVLCWLPL  
rVGLUT1      GYSHSKGVAISFLVLAVGFSG-FAISGFNVNHLDIAPRYAS--ILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASG  
 
                     510       520       530       540       550       560            
             ....|....|....|....|....|....|....|....|....|....|....|....|....|... 
LacY_1PV7_A  PGP-----------------------------LSLLRRQVNEVA------------------------  
GlpT_1PW4_A  EK-------------------------------RRHEQLLQELVPR----------------------  
EmrD_2GFP_A  --------------------------------------------------------------------  
rVGLUT1      EKQPWAEPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
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MSA with the amino acid substitution matrix based on genetic algorithm-based optimization of hydrophobicity (Zviling 2005).  TmA 157. 
 
                      10        20        30        40        50        60        70        80        90       100 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  ----------------------------MYYLKNTN-----------------FW--------MFGLFFFFYFFIMGAYFPFFPIWLHDINHISKSD---  
GlpT_1PW4_A  ----------------------------GSIFKPAPHKARLPAAEIDP--TYRRLRW------QIFLGIFFGYAAYYLVRKNFALAMPYLVEQGFSR---  
EmrD_2GFP_A  ------------------------------------------------------LLL------MLVLLVAVGQMAQTIYIPAIADMARDLNVREGA----  
rVGLUT1      MEFRQEEFRKLAGRALGRLHRLLEKRQEGAETLELSADGRPVTTHTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG  
 
                     110       120       130       140       150       160       170       180       190       200 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  ---------------TGIIFAAISLFSLLFQPLFGLLSDKLGLRKYLLWIITGMLVMFAPFFIFIFGPLLQYNILVG-SIVGGIYLGFCFNAGAPAVEAF  
GlpT_1PW4_A  -------------GDLGFALSGISIAYGFSKFIMGSVSDRS-NPRVFLPAGLILAAAVM--LFMGFVPWATSSIAVM-FVLLFLCGWFQGMGWPPCGRTM  
EmrD_2GFP_A  ---------------VQSVMGAYLLTYGVSQLFYGPISDRV-GRR---PVILVGMSIFM--LATLVA-VTTSSLTVL-IAASAMQGMGTGVGG-VMARTL  
rVGLUT1      HVVVQKAQFNWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFAIVATSTLNM--LIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWA  
 
                     210       220       230       240       250       260       270       280       290       300 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  IEKVSRR---SNFEFGRARMFGCVGWALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKTDAP--SSATVANAVG-----ANHSAFSLKLALELFR  
GlpT_1PW4_A  VHWWSQKERGGIVSVWNCAHNVGGGIPPLLFLLGMAWFNDWHAALYMPAFCAILVALFAFAMMRDTPQSCGLPPIEEYKNDYPDDYNEKAEQELTAKQIF  
EmrD_2GFP_A  PRDLYER---TQLRHANSLLNMGILVSPLLAPLIGGLLD---TMWNWRACYLFLLVLCAGVTF------SMARWMPETR----PVDAPRTRLLTSYKTLF  
rVGLUT1      PPLERSR---LATTAFCGSYAGAVVAMPLAGVLVQYSGWS--SVFYVYGSFGIFWYLFWLLVSYESP-ALHPSISEEERKYIEDAIGESAKLMNPVTKFN  
 
                     310       320       330       340       350       360       370       380       390       400 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  QPK---LWFLSLYVIGVSCTYD---------VFDQQFANFFTSFFATGEQGTRVFGYVTTMGELLNASIMFFAPLIINRIGG-----KNALLLAGTIMSV  
GlpT_1PW4_A  MQY--VLPNKLLWYIAIANVFVYLLRYGILDWSPTYLKEVKHFALDKSSWAYFLYEYAGIPGTLLCGWMSDKV-FRGNRGAT----GVFFMTLVTIATIV  
EmrD_2GFP_A  GNS--GFNCYLLMLIGGLAGIA---------AFEACSGVLMGAVLGLSSMTVSILFILPIPAAFFGAWFAGR---PNKRFST----LMWQSVICCLLAGL  
rVGLUT1      TPWRRFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRHIMSTTNVRKLMNCGGFGMEATLL  
 
                     410       420       430       440       450       460       470       480       490       500 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
LacY_1PV7_A  RIIGSSFATSALEVVILKTLHMFEVPFLLVGCFKYITSQFEVRFSATIYLVCFCFFKQLAMIFMSVLAGNMYESIGFQGAYLVLGLVALGFTLISVFTLS  
GlpT_1PW4_A  YWMNPAGNPTVDMICMIVIGFLIYGPVMLIGLHALELAPKKAAGTAAGFTGLFGYLGGSVAASAIVGYTVDF-FGWDGGFMVMIGGSILAVILLIVVMIG  
EmrD_2GFP_A  LMWIPDWFGVMNVWTLLVPAALFFFGAGMLFPLATSGAMEPFPFLAGTAGALVGGLQNIGSGVLASLS-----AMLPQTGQGSLGLLMTLMGLLIVLCWL  
rVGLUT1      LVVGYSHSKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASG  
 
                     510       520       530       540       550       560            
             ....|....|....|....|....|....|....|....|....|....|....|....|....|... 
LacY_1PV7_A  GPGPLS-----------------------------LLRRQVNEVA-----------------------  
GlpT_1PW4_A  EKRRHEQ----------------------------LLQELVPR-------------------------  
EmrD_2GFP_A  P----------------------------------L--------------------------------  
rVGLUT1      EKQPWAEPEEMSEEKCGFVGHDQLAGSDESEMEDEVEPPGAPPAPPPSYGATHSTVQPPRPPPPVRDY  
